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1. General Introduction 
It has been long recognised that damage to the adult mammalian central 
nervous system (CNS) is irreversible. However, it was not until early in the 20th 
century that Ramon y Cajal made the observation that while the CNS does not 
regenerate, the peripheral nervous system (PNS) of adult mammals does (Ramon y 
Cajal, 1928). He concluded that CNS axons do not regrow because of the presence 
of CNS-specific obstacles in their path. Since that time, a tremendous effort has 
been made to identify the characteristics of the PNS that allow regeneration, with 
the goal of converting the physiology of damaged CNS neurones to that of the PNS 
after injury, including regeneration and restored function. Unfortunately, this 
objective has not yet been achieved, because we still do not completely know the 
mechanisms of PNS regeneration. It is the goal of my work to better understand the 
regulation of this process. 
 
1.1. Peripheral nervous system regeneration and its regulation 
After peripheral nerve injury myelin debris is cleared by macrophages. 
Schwann cells de-differentiate, down-regulate the expression of myelin proteins 
and create a permissive environment for axonal regeneration. PNS axons can then 
regenerate between these permissive Schwann cells and the basal lamina (Fawcett 
and Keynes, 1990). Wallerian degeneration refers to the events that occur distal to 
the site of the injury. During the first week after axotomy axons fragment, are 
phagocytosed, and the myelin sheaths separate at incisures, breaking up into so- 
called ovoids. Over the next few weeks, these myelin ovoids are also phagocytosed 
in part by Schwann cells, but mainly by macrophages that invade the degenerating 
nerve. The clearance of myelin debris by macrophages promotes axonal 
regeneration (Dahlin, 1995). Schwann cells undergo extensive proliferation 
between the 3rd and 5th day post-axotomy (Jessen and Richardson, 2002). The basal 
lamina persists and surrounds the column of “denervated” Schwann cells. 
Proximal to the lesion site, axons give rise to one or more sprouts, each of 
which is tipped by a growth cone (Ramon y Cajal, 1928). For axonal regeneration 
to be successful, growth cones must first reach the distal nerve stump, which they 
do even if they have to cross a small gap between the proximal and distal nerve 
stumps. Upon reaching the distal nerve stump, growth cones enter “Schwann 
tubes”, the Schwann cells and their basal laminae, which provide the sole pathway 
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for regenerating axons in the distal nerve stump (Ramon y Cajal, 1928). Eventually, 
Schwann cells establish a 1:1 relationships with each fiber, synthesise a new basal 
lamina and form myelin sheaths. A crucial role in this process is again assigned to 
macrophages, which, along with endoneurial fibroblasts, provide recycled 
lipoproteins for Schwann cell myelination. With time, remyelinated axons may 
enlarge to nearly normal diameters and the localisation of ion channels is re-
established. However, the axo-glial junctions of remyelinated fibers are probably 
not as “tight” as those in unlesioned nerves, since regenerated nerves are more 
affected by potassium channel blockers (Jessen and Richardson, 2002).    
Although many tissues and substrates will support axonal regeneration, none 
are as potent as a degenerating peripheral nerve, which appears to be uniquely 
adapted for this role (Ide et al., 1996). The degradation of myelin in lesioned 
nerves and denervated Schwann cells appear to be key factors that promote axonal 
regeneration (Jessen and Richardson, 2002). Schwann cells contribute several 
molecules that promote neurite outgrowth, including extracellular matrix molecules 
and cell adhesion molecules on their cell membrane (Wagner et al., 2002). They 
appear to be the main source of many trophic factors, including the mitogen(s) that 
stimulate their own proliferation, but fibroblasts and macrophages also contribute 
to the supply of  neurotrophic factors. In addition to providing trophic (nurturing) 
factors, they supply tropic (guidance) factors that affect regenerating axons to 
guide their growth toward the distal nerve stump and enter Schwann tubes (Jessen 
and Richardson, 2002). Recently one particular family of neurotrophic molecules 
and its signalling have gained particular importance – the β-Neuregulin-1 family. 
 
1.2. β-Neuregulin-1 and its signalling      
The β-Neuregulins-1 (β-NRG-1) are a family of alternatively spliced, soluble 
and membrane bound proteins encoded by four known genes, three of which are 
expressed at high levels by PNS and CNS neurons during development (Buonanno 
and Fischbach, 2001). They are part of the epidermial growth factor (EGF) 
superfamily of growth factors that also includes the transforming growth factor 
alpha. Like all members of this family, β-NRG-1 mediates its effects by binding to 
and activating members of the erbB receptor tyrosine kinase family, which includes 
the EGF receptor (erbB1), erbB2, erbB3 and erbB4 (Tzahar et al., 1996). β-NRG-1 
binds preferentially to the erbB3 and erbB4  receptors, which then form 
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heterodimers by recruiting either erbB1 or erbB2 co-receptors to propagate 
signalling (Wiley, 2003). In the PNS erbB2 is the preferred receptor tyrosine 
kinase. Homodimers of erbB4 are also signal competent (Murphy et al., 2002; 
Carpenter, 2003). Ligand-induced dimerization activates receptor kinase activity 
and the phosphorylation of tyrosine residues in the C-terminal tail. These 
phosphorylated tyrosines, as part of a consensus motif, serve as binding sites for 
signalling molecules containing Src homology or phosphotyrosine binding domains. 
Depending on the constituents of the erbB dimer, NRGs can activate several 
cellular signalling cascades, including Ras/Raf, Jak/STAT, PI3K and PLCγ 
cascades (Murphy et al., 2002; Citri et al., 2003). Cyclin D1 is a central effector of 
signalling by erbBs and has been implicated as the major player in the promotion of 
cell cycle progression by the neuregulin pathway (Citri et al., 2003).  
The functions of β-NRG-1 include the regulation of the early cell fate 
determination, differentiation, migration, survival and maturation of satellite cells, 
Schwann cells and oligodendrocytes (Buonanno and Fischbach, 2001). Moreover, 
β-NRG-1 is a component of the “axon-associated mitogen” expressed by neonatal 
sensory neurons (Dong et al., 1999b). In the light of these developmental functions, 
it is possible that members of the neuregulin family, acting as axon-derived 
mitogen, promote Schwann cell proliferation also during Wallerian degeneration of 
adult peripheral nerves (Caroll et al., 1997). In the adult nervous system β-NRG-1 
mRNA is detectable in neurons projecting into the sciatic nerve (lumbar DRG and 
spinal cord), as well as in brain and skeletal muscle (Buonanno and Fischbach, 
2001). Schwann cells continue to express erbB2 and erbB3 throughout adulthood, 
although at reduced levels (Grinspan et al., 1996). Recent studies indeed suggest 
that β-NRG-1 may play a significant role during Wallerian degeneration, because 
the expression of various β-NRG-1 isoforms and of erbB2 and erbB3 by Schwann 
cells increases substantially during Wallerian degeneration (Caroll et al., 1997; 
Kim et al., 2002) and demyelination (Hall et al., 1997).  
 
1.3. Molecular mechanisms of Wallerian degeneration 
The molecular mechanisms that trigger Wallerian degeneration are unknown. 
Possibly, axotomy interrupts the supply of neuronal factors that maintain the 
myelinating phenotype of Schwann cells. On the other hand, a positive signal 
resulting from axonal degeneration may be involved (Fawcett and Keynes, 1990). 
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The main molecular features of Wallerian degeneration are the down-regulation of 
myelin-related genes and the up-regulation of nerve growth factor (NGF), the low 
affinity NFG receptor (NGFR/p75) and tenascin-C (Brown et al., 1991). Recently 
the early activation of another molecule, receptor tyrosine kinase erbB2, was 
shown. Within one hour following nerve transection, erbB2 is selectively 
phosphorylated as well as its downstream signals including Akt protein and the 
induction of the immediate early genes within the Schwann cell nuclei (Kim et al., 
2002). The role of the increased expression of β-NRG-1 and the activation of erbB2 
during Wallerian degeneration is speculative so far. The β-NRG-1 would be 
expected to promote the proliferation and survival of Schwann cells in the distal 
stump. However, the maximal expression of β-Neuregulin-1 and its receptors 
occurs later than the peak of Schwann cell proliferation and persists after 
proliferation has declined (Caroll et al., 1997). Thus, while β-NRG-1 receptor 
activation may potentiate Schwann cell proliferation, it is unlikely to initiate it. 
Nevertheless, recent studies using co-cultures of Schwann cells and neurons 
(Zanazzi et al., 2001) indicate that β-NRG-1 can itself promote Schwann cell de-
differentiation and demyelination, even in the absence of nerve injury. These 
findings suggest that activation of signalling pathways by β-Neuregulin-1 may 
contribute to the ongoing demyelination that is associated with nerve injury.    
Axon-Schwann cell interactions during regeneration are believed to be 
fundamentally similar to those that occur during development (Jessen and 
Richardson, 2002). Many transcriptional regulators implicated in the regulation of 
axonal regeneration (including Wallerian degeneration) are also assumed to 
regulate the metabolic state of developing neurons and Schwann cells. One 
candidate is the transcriptional activator retinoic acid which is an important 
morphogen in the development of many organ systems. 
 
1.4. The retinoic acid signalling system and its contribution to nerve 
regeneration    
Retinoids are vitamin A (retinol) derivatives. The most notable is retinoic 
acid, many biological effects of which are well known. It induces the 
differentiation of various populations of neurons and glia cells in embryonic spinal 
cord, cerebellum, dorsal root ganglia and sympathetic ganglia. As shown in this 
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thesis, it may also contribute to the signalling following nerve injury, when growth-
related genes need to be reactivated.  
Retinoic acid (RA) is a low molecular weight lipophilic molecule, whose 
synthesis is catalysed locally by aldehyde dehydrogenases (RALDH; Ross et al., 
2000; Zhao et al., 1996) in the presence of cellular retinol binding protein I (CRBP-
I; Napoli, 1996). Once RA enters the cell, it binds to cellular retinoic acid binding 
protein II (CRABP-II) and is transferred to the nucleus (Budhu and Noy, 2002). 
There it establishes or changes gene expression by binding to retinoic acid 
receptors (RARs) and retinoid X receptors (RXRs), which act as ligand-activated 
transcription factors. In mammals there are three RARs (-α, −β, and −γ) and three 
RXRs (-α, −β, and −γ), each of which has multiple isoforms. The RARs/RXRs act 
as heterodimers and recognise consensus sequences known as retinoic acid 
responsive elements (RARE) in the up-stream promoter sequences of RA-
responsive genes (Bastie et al., 2001; Delva et al., 1999). In addition to the 
regulation of RARE-containing genes, retinoid receptors affect the transcriptional 
activity of AP-1 – another important transcriptional factor (Lin et al., 2002). 
While the biological functions of retinoids in development have been studied 
in great detail, much less evidence exists so far that RA has physiological 
importance in the adult nervous system. Except for brain areas involved in bird 
song (Denisenko-Nehrbass et al., 2000) and the retina, where RA may be involved 
in circadian rhythms of gene expression (McCaffery et al., 1993) and gating of 
electrical synapses (Zhang and McMahon, 2001), no endogenous function for RA in 
the mature nervous system has been demonstrated either in healthy individuals or 
under pathological conditions.  
Only recently some publications appeared about the possible role of retinoic 
acid during regeneration. In various cell cultures retinoids were found to interact 
with most cytokine signals that mediate cellular interactions after nerve lesion in 
vivo (Mey, 2001). RA induces the “super-regeneration” of organs that can already 
regenerate, such as the urodele amphibian limb by re-specifying positional 
information in the limb (Maden, 1998). In organs that cannot normally regenerate, 
such as the adult mammalian lung, RA induces the complete regeneration of alveoli 
that have been destroyed by various forms of noxious treatment (Belloni et al., 
2000).  
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As for nervous system regeneration, RA induces neurite outgrowth in explant 
cultures of spinal cord from embryonic but not from adult mice. This decline in the 
regeneration-inducing potential of RA seems to be due to the loss of  RARβ2 
(Corcoran et al., 2000; Corcoran et al., 2002), because after transfection to the 
adult spinal cord, RARβ2 induced neurite outgrowth. This was observed even when 
no RA was added to the medium, implying an endogenous source of the needed 
ligand in the tissue. These data and experiments with retina and dorsal root ganglia 
demonstrate that retinoic acid is able to induce the regeneration of differentiated 
CNS neurons, when allowed to act on the genome through its normal pathway of 
receptors (Corcoran and Maden, 1999; Maden and Hind, 2003; Mey and Rombach, 
1999). 
 
1.5. Goals  
The scientific goal of this project is to investigate the role of retinoic acid 
signal transduction following nerve injury of the peripheral nervous system. 
Abundance in PNS and changes in gene expression of (1) enzymes involved in 
retinoid metabolism, of (2) cellular retinoid binding proteins and of (3) nuclear 
receptors for retinoids will be monitored after nerve lesion. The physiological 
relevance of the altered retinoid signalling will be measured in the primary 
Schwann cell cultures by (4) monitoring the expression of β-Neuregulin-1 receptors 
erbB2 and erbB3. 
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2. Materials and Methods 
 
2.1. Animal experimentation and surgical procedures 
Since the project aims at strategies for medical intervention and since injury-
related physiology differs fundamentally between vertebrate classes, the 
experiments require mammalian species. We chose rat sciatic nerve, because it is 
the largest peripheral nerve and there are established model systems for its 
regeneration. Mouse sciatic nerves were also studied since the in situ hybridisation 
probes were available only for this species. 
A total of seventy adult male Sprague-Dawley rats weighing 150-300 g were 
used. Animals were kept under a 12-h light/dark cycle in the animal care facility. 
Animals had unlimited access to rat chow and water. Rats were deeply 
anaesthetised with intraperitoneal injection of 10% ketamine hydrochloride 
(Sanofi-Ceva); (0,1ml/100g body weight) and 0.1 ml Rompun (Bayer). Under 
aseptic conditions, the right sciatic nerve was exposed and a lesion was performed 
(Fig. 2.1). The nerve was crushed once with jeweller’s’ forceps for 10 s or 
completely transected and the distal stump sutured to the muscle. After a survival 
period of 30 minutes, 1, 2, 4, 7 or 14 days the animals were sacrificed (overdose of 
sodium-pentobarbital) to obtain a 1 cm nerve segment distal to the lesioned site. 
Contralateral nerves were used as controls. For quantitative RT-PCR analyses, L4-
L6 dorsal root ganglia (DRG) ipsilateral and contralateral to the crushed sciatic 
nerves were also collected. The nerves and L4-L6 DRGs were washed in RNase-
free 0.1 M phosphate buffered saline (PBS) and snap frozen in liquid nitrogen to 
maintain the RNA intact. Preparation instruments were cleaned with RNase Away 
(Molecular Bio Products) to eliminate RNase-contamination.  
 
 
Fig. 2.1 Surgical procedure. 
A 10 s crush lesion was per-
formed to induce regene-
ration of the right sciatic ner-
ves of adult rats or mice. For 
the investigation of Wallerian 
degeneration the nerve was 
completely transected and the 
distal stump was sutured to 
the muscle.  
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Twenty adult female NMRI mice weighing 25-30 g were also used in this 
study. To induce regeneration, mice were anaesthetised with intraperitoneal 
injection of Avertin [1.25% 2,2,2-tribromoethanol (Sigma); 0.8% amyl alcohol 
(Sigma); 300µ l/10g body weight] and the right sciatic nerve was exposed and 
crushed once as described for rat experiments (see Fig. 2.1.). After survival periods 
of 24 hours or 7 days the animals were sacrificed [inhalation of diethyl-ether 
(Merck)] to obtain a 0.5 cm nerve segment distal to the lesioned sites. Contralateral 
nerves were used as controls. Mouse nerves were used exclusively for in situ 
hybridisation experiments and therefore prepared in RNase free conditions as 
described above. All procedures were conducted in accordance with the animal 
protection laws and were approved by Regierungspräsidium Köln, 
Tierversuchsgenehmigungen AZ 23.203.2 AC 29, 8/97 and AZ 23.203.2 AC 29, 
34/00. 
 
2.2. Schwann cell cultures 
In order to investigate physiological effects of retinoic acid, primary Schwann 
cell cultures from P0 Sprague-Dawley rats were established as previously described 
(Johann et al., 2003). Briefly, in one preparation 18 - 24 sciatic nerves were 
dissected, freed from blood vessels and fatty tissue, cut up in small pieces and 
digested for 1 h at 37°C in 10 ml Dulbecco´s Modified Eagle´s Medium (DMEM) 
containing 0.6% collagenase and 2.5% trypsin. To obtain single cells the nerve 
pieces were gently triturated (0.7 mm, then 0.4 mm gauge canulae). The cell 
suspension was plated out in uncoated culture flasks (25 cm2) with 5 ml DMEM 
containing 10 % heat-inactivated fetal calf serum (FCS). Fibroblast growth was 
reduced by the addition of 10 µ M cytosine arabinoside to the medium for one day. 
To eliminate remaining fibroblasts, the cells were incubated 20 min with Thy 1.1 
antibody (Sigma) at 37°C followed by treatment with baby rabbit complement 
(Linaris) for another 20 min. Schwann cells were then cultured in poly-L-lysin-
coated flasks (25 cm2) in 4 ml DMEM supplemented with 10 % FCS, 2 µ M 
forskolin (ICN) at 37 °C, 5 % CO2 and 100 µ g/ml bovine pituitary extract (Life 
Technologies; Johann et al., 2003). After the cells had reached confluence, 
complement lysis was repeated and cells were checked with microscopical 
inspection to ascertain the absence of fibroblasts.
 
For retinoic acid treatment, cells 
were cultivated in medium without forskolin. Final concentrations of  0.1, 1, 10, 
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100 and 1000 nM all-trans RA (stock solutions 0.1 µ M - 1 mM in dimethyl 
sulfoxide, DMSO) were added and cells were kept in darkness for 24 or 40 hrs at 37 
°C, 5 % CO2. Control cells received an equal volume of DMSO. For further RNA 
isolation or immunoblotting cells were harvested by centrifugation and re-
suspended in Trizol (for RNA isolation) or hypotonic buffer (for SDS-PAGE).  
 
2.3. Immunocytochemistry 
The avidin-biotin interaction provides a simple and sensitive method to 
localise antigens in tissues. It involves the application of biotin-conjugated 
secondary antibody followed by the addition of avidin-biotin-peroxidase complex. 
During formation of the complex, avidin acts as a bridge between biotin-labelled 
peroxidase molecules. Consequently, a “lattice” complex containing several 
peroxidase molecules is formed (Hsu et al., 1981). Binding of this complex to the 
biotin-labelled secondary antibodies results in a high staining intensity after the 
subsequent enzyme reaction. 
The use of horseradish peroxidase (HRP) for enzyme-mediated 
immunodetection, commonly referred to as immunoperoxidase labelling, is a well-
established cytochemical technique. The most widely used HRP substrate for these 
applications is diamino-benzidine (DAB), which generates a brown-coloured 
polymeric oxidation product. The DAB reaction product is discretely localised at 
HRP-labelled sites, providing high resolution images of sub-cellular antigen 
distribution. DAB staining can be visualised directly by bright-field light 
microscopy. 
To perform this technique, intact sciatic nerves from adult rats were used. For 
this both sciatic nerves were sampled and washed in 0.1 M PBS. Following fixation 
of 1 hour in cold 96% ethanol (Roth), the nerves were cryoprotected in 25% sucrose 
(Sigma) for at least 12 hours. To obtain longitudinal sections, sets of three nerves 
were embedded in Tissue Tek (Sakura) and cut with a cryostat (Leica) in 20 µ m 
sections. The sections were collected with gelatin-coated (to achieve better 
adhesion) microscope slides. Series of eight slides were prepared for each nerve. 
Each slide was then processed for antibody staining. For this method the primary 
antibodies listed in Tab. 2.1 and biotin-conjugated secondary antibodies goat anti-
mouse and goat anti-rabbit were used. 
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The following schema was used for this method, all steps were performed at room 
temperature (RT) except where stated otherwise: 
• Blocking of unspecific binding sites (0.4% Triton X-100 in 0.5 M Tris 
and 4% normal goat serum), 1h 
• Washing [0.1 M tris buffered saline (TBS; 0.05 M Tris, 0.85% NaCl, 
pH 7.4)], 2x5 min 
• Incubation with the primary antibody (0.04% Triton X-100 in 0.5 M 
Tris and 1% NGS; antibodies (AB) working dilutions are listed in Tab. 
2.1), 12h, 4°C, moist 
• Washing (0.1 M TBS), 2x5 min, 1x10 min 
• Blocking of endogenous peroxidase activity (1% H2O2 in 0.5 M Tris), 3 
min 
• Washing (0.1 M TBS), 2x5 min, 1x 10 min 
• Incubation with the secondary antibody (0.02% Triton X-100 in 0.5 M 
Tris; AB working dilutions are listed in Tab. 2.1), 2h, moist 
• Washing (0.1 M TBS), 2x5 min, 1x 10 min 
• Incubation with avidin-biotin-peroxidase complex [1% bovine serum 
albumin (BSA) in 0.5 M Tris with ABC Kit (Vector)], 1.5 h, moist 
• Washing (first: 0.1 M TBS, 2x5 min; then: acetate-imidazole buffer 
(1M sodium acetate, pH 7.2; 0.2 M imidazole, 2x5 min)  
• Chromogen reaction (100 mM NiSO4; 125 mM sodium acetate; 10 mM 
imidazole; 0.03% 3,3-diaminobenzidine (DAB);  0.003% H2O2, pH 6.5) 
15 – 30 min 
• Washing (first: acetate-imidazole buffer, 2x5 min, 1x10 min; then: 0.1 
M TBS, 2x5 min)  
• Slides mounting with glycerol, visualisation of the precipitate 
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Table 2.1. Antibodies used for immunocytochemistry (IC) and Western blotting 
(WB). 
Antibody 
Manufacturer, 
catalogue Number 
Working 
dilution, IC 
Working 
dilution,  WB 
RARα Santa Cruz (sc-551) 1:200 1:500 
RARβ Santa Cruz (sc-552) 1:200 1:500 
RARγ Santa Cruz (sc-7387) 1:200 1:500 
RXRα Santa Cruz (sc-553) 1:200 1:500 
RXRβ Santa Cruz (sc-831) 1:200 1:500 
RXRγ Santa Cruz (sc-555) 1:200 1:500 
CRABP-II Gift from P.Chambon -- 1:1000 
S-100 Sigma (S2644) 1:100 -- 
erbB3 Santa Cruz (sc-285) -- 1:200 
GAM: goat  
anti-mouse Ig  
Sigma (A3682) 
peroxidase-conjugated -- 1:5000 
GAR: goat  
anti-rabbit Ig 
Sigma (A6154) 
peroxidase-conjugated -- 1:10000 
GAM: goat  
anti-mouse Ig  
Vector (BA-2000) 
biotin-conjugated 1:1000 -- 
GAR: goat  
anti-rabbit Ig 
Vector (BA-1000) 
biotin-conjugated 1:1000 -- 
 
 
2.4. In situ Hybridisation 
In situ hybridisation (ISH) techniques allow specific nucleic acid sequences to 
be detected in morphologically preserved cells or tissue sections. Thus in situ 
hybridisation can relate microscopic topological information to gene activity at the 
mRNA level. In situ hybridisation requires a probe which contains a reporter 
molecule that can be detected by affinitiy cytochemistry. The reporter molecule is 
accessible to modified antibodies, which are then detectable in chromogen reaction.   
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2.4.1. Preparation of slides and fixation of the material 
In order to detect the presence of retinaldehyde dehydrogenases (RALDHs) in 
sciatic nerves after the injury, the right sciatic nerves of 20 NMRI mice were 
crushed as described in 2.1. Since in situ hybridisation detects the molecules on 
mRNA level, all procedures were performed in RNase free conditions. This was 
achieved by cleaning all needed instruments with RNase Away (Molecular Bio 
Products). After washing in 0.1 M PBS, sciatic nerves were fixed in 4% 
paraformaldehyde (PFA) for 2 h at RT. Following fixation, the nerves were 
cryoprotected in 25% sucrose (Sigma) for at least 12 hours. To obtain longitudinal 
sections, each three nerves were embedded in Tissue Tek (Sakura) and cut with a 
cryostat (Leica) in 15 µ m sections. The sections were collected with gelatin-coated 
microscope slides. Series of eight slides were prepared from each nerve. 
 
2.4.2. Synthesis of single-stranded digoxigenin-labelled RNA probes for ISH 
by in vitro transcription of double-stranded DNA templates  
Double-stranded DNA templates which encode the gene of interest must be 
inserted into transcription vectors. The cloning procedure was performed in the 
laboratory of Dr. P. McCaffery (Harvard medical school, Boston). Vectors with 
inserted RALDH-1 and RALDH-2 partial sequences were provided.  
Most transcription vectors are derived from plasmids and contain at least one 
of the three bacteriophage RNA polymerase promoters situated adjacent to a 
multiple cloning site. The designed restriction sites are presented at 5' and 3' of the 
insert. In this study pBluescript (Stratagene) phagemids were used. This vector has 
dual promoters - T3 and T7 – at either side of synthetic polylinker containing 23 
unique restriction enzyme sites. These sites generate 5' and 3' sticky and blunt ends 
and generally allow the directional cloning of DNA inserts. pBluescript carries the 
regulatory sequences and amino terminus coding region of the E. coli β-
galactosidase (lacZ) gene, which allows α-complementation when pBluescript is 
transformed into a bacterial host. The polylinker and both flanking promoters are 
situated within the lacZ coding region. Successful subcloning into the polylinker 
disrupts lacZ and results in a non-functional peptide. This allows screening by blue 
(non-recombinant) / white (recombinant) colony selection after induction of lacZ 
and incubation of bacteria on X-gal substrate.  
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After selection of the transfected colony, it was placed in the new vehicle and 
allowed to generate a liquid culture in LB medium (10% trypsin, 5% yeast extract, 
10% NaCl) with 4% ampicillin by 37°C for 12 h. Afterwards plasmid DNA was 
isolated with Qiagen Plasmid Purification Kit (Qiagen) according to the 
manufacturers instructions.  
Thereafter, in vitro transcription of insert DNA into complementary RNA was 
done according to the following scheme:  
• Linearisation of DNA template with EcoR1 restriction enzymes, 2 h, 
37°C 
• Quality check: 0.8% agarose gel electrophoresis  
• Evaporation (purification of DNA template from restriction enzymes 
and protein traces): 1) 3 M sodium acetate and 100% 
phenol/chloroform, centrifugation 12000 x g (10 min), DNA in the 
supernatant. 2) 95% ethanol, incubation at -80°C, 30 min followed by 
centrifugation 12000 x g (10 min), DNA is in pellet. RNase free 
conditions were followed from here on. 
• Transcription of linear DNA with digoxigenin (DIG). DIG-labelled 
dNTP mix was used to generate RNA. For transcription of RALDH-1 – 
T3 RNA polymerase, for RALDH-2 – T7 RNA polymerase (MBI 
Fermentas) were used, 1 h, 37°C 
• Removal of the rest DNA template with DNase I (Invitrogen), 15 min, 
RT; inactivation of the enzyme with 25 mM EDTA, 10 min, 65°C 
• Purification and precipitation of the ready to use RNA-riboprobe with 4 
M LiCl and 100% ethanol 
• Dissolvement in diethyl-pyrocarbonate (DEPC)-treated H2O 
The labelling method is based on a digoxigenin steroid isolated from digitalis 
plants (Digitalis purpurea), which are the only natural source of digoxigenin. 
Digoxigenin is linked to the C-5 position of uridine nucleotides via a spacer arm 
containing eleven carbon atoms. Hybridised DIG-labelled probes may be detected 
with high affinity anti-digoxigenin (anti-DIG) antibodies that are conjugated to 
alkaline phosphatase. In this case the visualisation is obtained with the colorimetric 
(NBT and BCIP) alkaline phosphatase substrates.  
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2.4.3. In situ hybridisation  
My in situ hybridisation procedures followed this protocol: 
• Pre-incubation washes. Serve to re-hydrate tissue sections, to enable 
the access of proteases to the tissue (ethanol series of 100%, 95%, 70%, 
50% in 0.3 M NaCl and 0.03 M sodium citrate (2xSSC); each 1x1 min, 
RT) 
• Protease treatment. Serves to increase target accessibility by digesting 
the proteins that surround the target nucleic acid (Protease K, 10 
mg/ml, 3 min, 37°C) 
• Washing, all at RT: 1) in DEPC-H2O, briefly; 2) 0.1 M triethanolamine 
solution (TEA), pH 8.0, 3 min; 2.6% acetic anhydride in 0.1 M TEA, 10 
min   
• Dehydration of the slides in ethanol series: 2xSSC, 50%, 70%, 95%, 
100%, each 1x1 min, RT   
• Riboprobe preparation. The probes were denaturated at 68°C, 10 min 
and added to the hybridisation mix [400 ng/ml in 50% formamide, 10% 
dextran sulfate, 1% Blocking reagent (Roche)]  
• In situ hybridisation. Prepared probes were spread on the slides, which 
were then covered with a slide cover and the edges sealed with DPX. 
Incubation 12 h at 68°C 
• Post-hybridisation washes with 1) 2xSSC, 55°C, 2x30 min; 2) 50% 
formamide, 55°C, 30 min; 3) 2xSSC, 37°C, 2x30 min 
• RNase treatment. This step is done in order to eliminate traces of 
unbound riboprobes, which would otherwise enhance background 
staining (RNase A 100 mg/ml in 0.01 M Tris, 0.001M EDTA, 3% NaCl) 
• Blocking of unspecific binding sites of the AB. 1) Incubation with 10% 
blocking buffer ( 2xSSC, 0.05% Triton X-100, 2% Blocking reagent 
(Roche), 2 h, RT; 2) 1x maleate buffer (0.58% maleic acid, 0.44% 
NaCl), 2x5 min, RT 
• Incubation with anti-DIG antibody (Roche, 1093274). Antibody 
dilution of 1:1000 was prepared in an antibody buffer (1x Maleate 
buffer, 0.3% Triton X-100, 2% Blocking reagent), incubation for 24 h, 
4°C, moist 
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• Post-incubation washes with 1) 1x Maleate buffer, 2x 10 min, RT; 2) 
Buffer 3 (100 mM Tris pH 9.5, 100 mM NaCl, 50 mM MgCl2, 1 mM 
Levamisole), 10 min, RT  
• Immunocytochemistry. Incubation with chromogen substrate (Buffer 3 
with 0.34% nitro blue tetrazolium chloride (NBT), 0.17% 5-Bromo-4-
chloro-3-indolyl phosphate, toluidine salt (BCIP), 12 h, RT, in darkness 
• Post-substrate wash with 1 mM EDTA, 0.9% NaCl, 0.01 M Tris-Cl, pH 
7.5; 30 min, RT 
• Mounting of slides with glycerol, visualisation of the precipitate 
 
2.5. RNA isolation, reverse transcription and PCR 
2.5.1. RNA isolation  
Total RNA was isolated from sciatic nerves, DRGs and Schwann cells using 
Trizol (Invitrogen) based on the method of Chomczynski and Sacchi (Chomszynski 
and Sacchi, 1987). For Schwann cell RNA isolation two culture flasks were pooled 
to generate one sample. RNA isolation followed the outline listed below: 
• Homogenisation. Incubation of tissues or cells with Trizol reagent 
(phenol-guanidine isothiocyanate), cells 5 min, nerves and DRGs 1 h; 
disruption of tissue residues with ultra-sound 
• Phase separation. Addition of chloroform (Sigma), centrifugation in 
order to separate RNA from DNA and proteins, 15 min, 12000 x g 
• RNA precipitation. Transfer of aqueous RNA phase to isopropyl 
alcohol in order to precipitate RNA, 1 h, -20°C. Since sciatic nerves are 
tissues with a low RNA yield, 1% glycogen was added to help pellet 
visualisation after centrifugation, 15 min, 12000 x g  
• RNA wash. After removing of supernatant, RNA pellet was briefly 
washed with 75% ethanol 
• Re-dissolving of RNA. After discarding of ethanol, RNA pellet was air 
dried and dissolved in DEPC-treated H2O 
• Estimation of RNA amount in the sample: photometrically the 
absorbence (A) of the RNA-water mixture at 260 nm was measured 
after the samples were diluted 1:100. The concentration of the total 
RNA was calculated as follows: A260 x 100 (1:100 dilution) x 40 
ng/µ l=[RNA] 
 - 17 - 
2.5.2. DNase treatment  
Samples of 2500 ng total RNA were treated with DNase I (Invitrogen) to 
eliminate traces of DNA. The following protocol was used for DNase treatment: 
• Addition of 5 units of DNase I and DNase reaction buffer, 15 min, RT 
• Inactivation of DNase I with 25 mM EDTA, 10 min, 65°C 
 
2.5.3. RT-PCR  
 500 ng of DNase treated RNA was reverse transcribed with oligo-dT-primer 
and Omniscript reverse transcriptase (Qiagen) according to the manufacturer's 
instructions. The rest of RNA was used as a negative control for PCR reactions. 
Reverse transcription (RT) followed this protocol: 
• Incubation of RNA with the following reagents: 1 µ M oligo-dT12-18-
primer (Invitrogen; binds to poly-A tail of mRNA, used as priming for 
reverse transcriptase), 1x RT Buffer, 0.5 mM of each dNTP,  0.5 
units/µ l of RNase inhibitor RNaseOUT (Invitrogen), 0.2 units/µ l of RT 
enzyme; 1 h, 37°C 
 
2.5.4. PCR  
Polymerase chain reaction (PCR) is an in vitro method for enzymatic 
amplification of defined sequences of DNA. The reaction uses two oligonucleotide 
primers that hybridise to opposite strands and flank the target DNA sequence that is 
to be amplified. The elongation of the primers is catalysed by a heat stable DNA 
polymerase. A repetitive series of cycles involving template denaturation, primer 
annealing, and extension of the annealed primers by the polymerase results in 
exponential accumulation of a specific DNA fragment. The ends of the fragment are 
defined by the 5’ ends of the primers (position in the sequence). Because the primer 
extension products synthesised in a given cycle can serve as a template in the next 
cycle, the number of target DNA copies approximately doubles every cycle. 
Analysis of PCR products is done by separation in agarose gel electrophoresis 
according to their molecular weight. The visualisation of products in the gel is 
possible with ethidium bromide, which integrates in the structure of nucleic acid 
and after absorption of UV-light at 312 nm emits fluorescence at 590 nm.       
Primer sequences for the amplification of the components of the retinoic acid 
system and erbBs are listed in Tab. 2.2. PCR primers from rat gene sequences were 
 - 18 - 
generated using software of Whithead Institute for Biomedical research 
(Cambridge, MA; http://www.genome.wi.mit.edu/cgi-bin/primer/primer3www.cgi) 
and synthesised at MWG-Biotech.  
 
Table 2.2. Primers used in PCR and quantitative “real-time” PCR. 
Gene Primer sequence (sense, antisense) Position in 
sequence 
Expected 
size of 
PCR 
fragment 
CRBP-I 
5´- ACGGGTACTGGAAGATGCTG -3´ 
5´- GGCCGCTCAGTGTACTTTCT -3´ 
111–130 
489–508 398 bp 
CRABP-I 
5´- GACGAAGGACCAGAATGGAA -3´ 
5´- GGCCCATCACTTCTTTTTGA -3´ 
58–77 
447–466 409 bp 
CRABP-II 
5´- CTTCAAGATCGGGGAGGAAT -3´ 
5´- TGGTATGGAGCTGGGACTTC -3´ 
189–208 
577–596 408 bp 
RARα  5´- CAGATGCACAACGCTGGC -3´ 5´- CCGACTGTCCGCTTAGAG -3´ 
886–903 
1263–1282 397 bp 
RARβ  5´- GCGGAGAGATCATGTTTGAC -3´ 5´- TGGCATCGATTCCTAGTGAC -3´ 
187–206 
579–598 412 bp 
RARγ 5´- GTGGAGACCGAATGGACC -3´ 5´- GACAGGGATGAACACAGG -3´ 
1328–1345 
1829–1848 521 bp 
RXRα 5´- CAATGGCGTCCTCAAGGTTC -3´ 5´- ACTCCACCTCGTTCTCATTC -3´ 
531–550 
837–856 326 bp 
RXRβ 5´- AGATCAACTCCACAGTGTCG -3´ 5´- TCTCCATCCCCGTCTTTGTC -3´ 
221–240 
589–608 388 bp 
RXRγ 5´- CTCAGCTCAATGTGGTCAAC -3´ 5´- CACATTCTGCCTCACTCTCT -3´ 
58–77 
425–444 387 bp 
RALDH-1 5´- CTCAGCTCAATGTGGTCAAC -3´ 5´- CACATTCTGCCTCACTCTCT -3´ 
1437–1456 
1821–1840 404 bp 
RALDH-2 5´- CTCAGCTCAATGTGGTCAAC -3´ 5´- CACATTCTGCCTCACTCTCT -3´ 
1020–1039 
1443–1462 443 bp 
RALDH-3 5´- CTCAGCTCAATGTGGTCAAC -3´ 5´- CACATTCTGCCTCACTCTCT -3´ 
1280–1399 
1658–1679 400 bp 
CYP26 5´- GTGCCAGTGATTGCTGAAGA -3´ 5´- TCCTCTCTCCCATGAGTGCT -3´ 
480–499 
850–869 390 bp 
erbB2 5´- CCCATCAGAGTGATGTGTGG-3´ 5´- TCATCTTCCAGCAGTGAACG-3´ 
2730-2749 
3047-3066 337 bp 
erbB3 5´- GAGGCTTGTCTGGATTCTGC-3´ 5´- GGTGTGTATCTGGCATGACG-3´ 
3319-3338 
3606-3625 307 bp 
GAPDH 5´- AGAACATCATCCCTGCATCC -3´ 5´- TTACTCCTTGGAGGCCATGT -3´ 
1454–1473 
1832–1851 398 bp 
-actin 5´- GAGCTATGAGCTGCCTGACG -3´ 5´- AGCACTTGCGGTCCACGATG -3´ 
636–655 
1026–1045 410 bp 
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PCR was performed according to following protocol: 
• 10 µ l volume of a ReadyMix REDTaq solution (Sigma) contained: 0.08 
mM dNTP (cATP, dCTP, dGTP, dTTP), 0.03 units/µ l REDTaq 
polymerase, 4 mM Tris-HCl, 20 mM KCl, 0.6 mM MgCl2, 0.0004% 
gelatin, stabilisers. To each ReadyMix aliquot 1 µ M of sense and 
antisense primer (see Tab. 2.2.) were added as well as 25 ng of cDNA. 
Negative controls (reactions to prove that no DNA contamination is 
present in the samples) were carried with the same volume of DNase I 
treated RNA instead of cDNA 
• Alternatively, Qiagen PCR Kit (Qiagen) was used. One reaction 
contained 1x PCR Buffer, 1x Q-solution, 5 mM MgCl2, 0.1mM each 
dNTP, 0.6 µ M of sense and antisense primer, 0.125 units/µ l Taq DNA 
polymerase and 25 ng of cDNA 
• Reaction parameters were: first denaturation 180 sec at 94°C, 30-35 
cycles of annealing 60 sec at 51°C, extension 90 sec at 72°C, 
denaturation 60 sec at 94°C, followed by 60 sec annealing and last 
elongation 600 sec at 72°C. (Annealing temperatures of 7°C below 
Tm’s of the primers were chosen for PCR).   
• The PCR products were separated by agarose gel electrophoresis and 
stained with ethidium bromide to verify their expected sizes 
 
2.6. Quantitative “real-time” PCR 
Analysing PCR products during ampification has become known as “real-
time” PCR. The easiest way to monitor PCR is with fluorescence. The most 
frequently used fluorescence dye used for “real-time” PCR is SYBR Green I, which 
has similar properties as ethidium bromide. As PCR progresses, double stranded 
DNA is synthesised and the fluorescence of SYBR Green I increases. Thus the 
amount of synthesised PCR product may be monitored after each cycle by 
fluorescence. If fluorescence is plotted against cycle number, the accumulation of 
PCR products produces a growth curve (Fig. 2.2.) with an initial phase (below the 
sensitivity of fluorimeter), an exponential phase, and a final plateau phase. 
Monitoring fluorescence after each cycle is a very convenient way to quantify the 
initial number of template copies (which conventional qualitative PCR does not 
permit). Higher concentrations of template shift the growth curve parallel to the 
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abscissa and to the earlier cycles (to the left). This shift can be quantified as a 
fractional cycle number and is inversely proportional to the log of the initial 
template concentration.  
 
 
 
Fig. 2.2 Example of typical Light Cycler PCR curves. Crossing points (X1 and 
X2) can be determined by “real-time” monitoring. 
 
The quantification was done using the following calculations:  
During the log phase the amplification is described by this equation: 
Cx = C0 × 2x,         (1) 
where Cx is the amount of target sequence at cycle x, C0 is the initial amount of 
target and “2” is the efficiency of amplification. However the replication of PCR 
product is achieved only in the ideal case, thus 
 Cx = C0 × ax where a ≤ 2       (2) 
In order to establish a (efficiency of amplification) a dilution series of cDNA were 
performed. For this three different cDNA concentrations  (C1 = 12.5 ng, C2 = 6.25 
ng and C3 = 3.125 ng) were tested for each primer pair and in the same Light Cycler 
PCR run. The point of the log phase begin (crossing point) for each cDNA 
concentration was empirically determined and identified here as x. Since C1/C2 = 
C2/C3 = 2, the equation (1) can be modified as follows:  
C1/C2 = a -∆x where ∆X = X1 – X2                                                                  (3) 
lg C1/C2 = -∆x × lg a         (3a) 
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a = 10 ((lg C1/C2)/-∆X)        (3b) 
C1/C2 = 2                                  (4) 
 a = 10 (0,301/-∆X)         (4a) 
The factor a is now used to calculate the relative amount of initial template in the 
experiment sample Cexperiment compared to Ccontrol: 
Cexperiment /Ccontrol = a -∆X       (5) 
∆X represents the curve shift (differences in the crossing points) between 
experimental and control samples: 
∆X = Xexperiment – Xcontrol       (6) 
These calculations were done for each primer pair investigated in this study: 
CRBP-I, CRABP-II, erbB2, erbB3, GADPH and β-actin and the PCR-efficiencies as 
were determined.  
To establish whether the initial cDNA amount is the same in each sample, the 
expression of house-keeping genes GAPDH and β-actin was used as positive 
controls. Ideally, the point of beginning of the log phase by GAPDH or β-actin 
amplification is same for experimental and control samples: 
 ∆X = 0          (7) 
(Cexperiment /Ccontrol)GAPDH = a -∆X = 1     (7a) 
However, this is not the case in most of the experiments and the concentration 
differences are < 1 or > 1, thus 
(Cexperiment /Ccontrol)GAPDH = a -∆X = Q     (7b) 
indicative of the differences of cDNA amounts in experimental and control 
samples. The quotient 1/Q was used as a correction factor for the sample 
comparison. For this, all obtained concentration differences for CRBP-I, CRABP-
II, erbB2 and erbB3 between experimental and control samples were multiplied by 
the correction factor (1/Q). 
The identification of PCR products was done by their melting temperature 
(Tm). It depends on the G:C content and the length of the synthesised product and 
can be calculated theoretically using this equation:  
Tm = 69.3 + 0.41×GC% – 650/sequence length    (8)  
To measure the relative change of mRNA expression quantitative PCRs were 
performed by means of the Roche Light Cycler System using the QuantiTect SYBR 
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Green PCR Kit (Qiagen) and Light Cycler Software, Version 3. Quantitative “real-
time” PCR was performed according to the following protocol: 
• 10 µ l volume of QuantiTect SYBR Green PCR Master Mix (Qiagen) 
contained: HotStarTaq DNA polymerase, Tris-HCl, KCl, (NH4)2SO4, 2.5 mM 
MgCl2, SYBR green I, dNTPs. To each aliquot of this Master Mix 0.5 µ M of 
sense and antisense primer (see Tab. 2.2.) and 12.5 ng of cDNA were added. 
Negative controls were carried out with the same volume of DNase I treated 
RNA instead of cDNA (i.e. omission of the RT-PCR step).  
• In order to determine primer and PCR efficiency three different 
concentrations of cDNA were tested for each primer pair: C1= 12.5 ng, C2= 
6.25 ng and C3= 3.125 ng. 
• The experimental protocol consisted of a first denaturation 15 min at 95°C, 
followed by 35-40 cycles of annealing 20 sec at 52°C (erbBs) or 58°C 
(CRBP-I, CRABP-II), amplification 20 sec at 72°C, fluorescence meas-
urement 5 sec at 81°C and denaturation 15 sec at 94°C. The expression of 
glyceraldehyde phosphate dehydrogenase (GAPDH) or β-actin was used as a 
non-regulated control. (Annealing temperatures were consistent with the 
Tm’s of the primers; on additional fluorescence measurement step at 81°C 
was required to omit primer dimmers built during amplification).       
• The identity of PCR products was confirming with melting curve analysis 
and agarose gel electrophoresis. 
• Logarithms of the mRNA ratios of RA different samples were calculated and 
corrected for differences in the extract concentrations based on the house-
keeping gene analysis. After confirmation of their normal distribution 
(Shapiro-Wilk W test) the effect was tested with ANOVA. Differences 
between the mean quotients and zero were tested with a two-tailed t-test 
using Bonferroni-Holm correction or Dunnett’s test. 
• The amplified DNA fragments of CRBP-I and CRABP-II were cloned 
(TOPO-TA cloning, Invitrogen) and sequenced (ZEDA, Frauenhofer Institut 
RWTH-Aachen).  
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2.7. SDS-PAGE and Western blotting  
2.7.1. Protein isolation and preparation 
For immunoblotting nerves were isolated as described in part 2.1 and 
sonicated in hypotonic buffer with a mix of protease inhibitors. Schwann cells were 
harvested as described in 2.2. and re-dissolved in the same buffer as the nerves.  
Hypotonic buffer consisted of 20 mM HEPES, 1 mM PMSF, 1 µM Leupeptin, 1% 
Aproptin, 1% Triton X-100. The protein concentration was measured using BCA 
test assay (Sigma). The principle of this test is based on the ability of proteins to 
reduce alkaline Cu(II) to Cu(I) in a concentration dependent manner. Bicinchoninic 
acid (BCA) is a highly specific chromogenic reagent for Cu(I) forming a purple 
complex with an absorbence maximum at 562 nm. The following protocol was used 
for the BCA test: 
• Generating protein standards (bovine serum albumin): 0.1, 0.2, 0.4, 0.8, 
1.4, 2, 3.2 µ g/µ l  
• Preparation of tested samples: dilution 1:10 
• Addition of 1x 4% Cu2SO4 and 50x BCA to protein standards and test 
samples 
• Incubation for 30 min. at 37°C, extinction measurement with ELISA-
reader at 630 nM 
• Calculating of the protein amount using calibration curve of known 
standards was done by linear regression 
 
2.7.2. SDS-PAGE  
SDS-PAGE (sodium dodecyl sulfate – polyacrylamide gel electrophoresis) is 
used to separate mixed protein samples according to size under denaturating 
conditions. Gel electrophoresis is a technique in which an electric current is used to 
move charged molecules through a gel-like matrix. Acrylamide is a 3-carbon amide 
which is polymerised to form long chains with cross-links between the chains. For 
SDS-PAGE, a discontinuous buffer system is used, where different buffer ions are 
present in the gel and electrode reservoirs. Using two different gel systems 
(stacking and resolving gels) enables the compression of the samples in a thin 
starting band followed by fine separation during electrophoresis. To achieve such 
separation proteins must first be denaturated by heating in buffer containing SDS 
and a thiol reducing agent 2-mercaptoethanol.   
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The protocol was performed according to the following protocol: 
• Generating of 10% resolving gel (Acrylamide/Bis (30% T, 2.67% C), 
10% SDS, 1.5 mM Tris-HCl pH 8.8, 10% APS, TEMED), 
polymerisation 2-3 h or overnight 
• Generating of 5% stacking gel (Acrylamide/Bis (30% T, 2.67% C), 10% 
SDS, 0.5 mM Tris-HCl pH 6.8, 10% APS, TEMED), polymerisation 1 h 
• Denaturation of proteins by heating with SDS and 2-mercaptoethanol 
and loading in the gel 
• Electrophoresis by 15 mA/ 2 cm gel (in stacking gel) and 30 mA/ 6 cm 
gel (in resolving gel); 1.5 h at RT. Electrophoresis buffer contained 25 
mM Tris, 192 mM glycine, 0.1% SDS and had pH 8.3  
 
2.7.2. Western blotting 
Separated by discontinuos SDS-PAGE proteins were transferred by blotting 
onto a nitrocellulose membrane. The transfer occurred in a gel cassette (Bio-Rad) 
and in the transfer buffer A (25 mM Tris, 192 mM glycine, 20% methanol, 0.1% 
SDS, pH 8.3) at 30 V and 90 mA for 16 h. Quantity check of the protein transfer 
was done by Ponceau-S-staining (3% Ponceau-S, 30% TCA, 30% Sulfosalicile 
acid), incubation for 5 min at RT. 
 
2.7.3. ECL 
Enhanced chemiluminescence (ECL) is based on the light emission resulting 
from the dissipation of energy from a substance in an excited state. The excitation 
is the effect of chemical oxidation of luminol under alkaline conditions and in the 
presence of phenol by horseradish/hydrogen peroxidase. Immediately following 
oxidation, the luminol is in an excited state which then decays to ground state via a 
light emitting pathway. The maximum light emission is at a wavelength of 428 nm, 
which can be detected by a short exposure of an autoradiography film. For ECL the 
same  antiserums were used as for immunocytochemistry (see Tab. 2.1), however, 
detection of immunoreactivity was based on peroxidase-conjugated goat anti-rabbit 
and goat anti-mouse secondary antibodies (see Tab. 2.1) and ECL kit (Amersham). 
X-ray films (Hyperfilm, Amersham) were exposed 30 sec – 10 min to determine the 
linear range of the signal.  
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ECL was performed according to the following protocol, all procedures at 
room temperature on an orbital shaker: 
• Blocking of non-specific binding sites by 10% bovine serum albumin 
(BSA) in Tris-buffered saline/Tween 20 buffer (TBS-T; 20 mM Tris, 
0.8% NaCl, 0.1% Tween 20, pH 7.6); 10 min (polyclonal AB) or 1 h 
(monoclonal AB) 
• Washing (TBS-T), 3x 15 sec 
• Incubation with the primary antibody (for dilutions see Tab. 2.1), 1h 
• Washing (TBS-T), 3x 15 sec, 1x 10 min 
• Incubation with the secondary antibody (for dilutions see Tab. 2.1), 15 
min 
• Washing (TBS-T), 3x 15 sec, 1x 10 min 
• Incubation with the detection solution (equal volumes of detection 
solution 1 with detection solution 2 from ECL kit) for 1 –  3 min 
• Film exposure 
• Evaluation with a digital image analysis system (LTF)   
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3. Results 
 
The scientific goal of this project is to investigate the role of retinoic acid 
(RA) signal transduction after peripheral nerve injury. While a number of indirect 
pieces of evidence suggested RA as a regeneration-associated signal, not even the 
presence of this molecule in the PNS of adult mammals was known at the beginning 
of my project. Thus, the first part of my thesis was devoted to determining the 
expression of molecules involved in RA signalling in the PNS. For this the 
expression of the RA-signalling cascade was tested in sciatic nerves and Schwann 
cells in vitro. The activity of RA is generally inferred from the local distribution of 
retinaldehyde dehydrogenases. Therefore their expression was evaluated by RT-
PCR and in situ hybridisation (3.1). Since cellular retinoid binding proteins also 
play important roles in retinoic acid signalling, the expression of CRBP-I and 
CRABP-II was evaluated and is described in (3.2). Transcriptional effects of 
retinoic acid are mediated via its receptors – ligand-activated transcriptional factors 
RARs and RXRs. Accordingly, their expression was measured during peripheral 
nerve regeneration (3.3). After establishing the fact that the retinoic acid system 
participates in the physiological reactions to nerve injury, the question about its 
physiological relevance arose. Taking into account the indirect evidence of RA-
system involvement in Wallerian degeneration, the expression of β-Neuregulin-1 
receptors erbB2 and erbB3 was measured in RA-treated Schwann cells in vitro 
(3.4), because these signals have been implicated as triggers of Wallerian 
degeneration. 
 
 
 
 
 
 - 27 - 
 
3.1. RA signalling in the PNS 
 
 
 
3.1.1. Abstract 
Although the specific roles of Schwann cells, neurons and macrophages in 
injury-induced processes have been established, much less is known about the 
regulation of their functions. I propose that the transcriptional activator retinoic 
acid (RA) might control some of these functions. Since Schwann cells are major 
players in the physiological interactions following peripheral nerve injury I 
addressed the question whether the retinoic acid signalling system is present in 
sciatic nerves and in Schwann cells in vitro. With RT-PCR all necessary compo-
nents of the RA signalling pathway were detected in the sciatic nerve of adult rats 
and in Schwann cell cultures. These are retinoic acid receptors, retinoid X re-
ceptors, the retinoic acid synthesising enzymes RALDH-1, -2, and -3, in addition, 
the cellular retinoid binding proteins CRBP-I, CRABP-I and -II. Even though the 
expression of RALDH-1 and RALDH-2 was not affected by the injury, the increase 
of retinoic acid responsive element (RARE) activity after crush suggests an 
involvement of RA in traumatic processes after peripheral nerve injury.  
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3.1.2. Introduction 
The understanding of molecular processes that cause success or failure of 
neuronal regeneration has become one of the main problems in medical 
neurobiology. The physiological reactions after nerve injury in the peripheral 
nervous system (PNS) are regulated by interactions between damaged neurones, 
glia cells (Schwann cells) and hematogenous cells of the immune system. On the 
molecular level these interactions are mediated by signal transduction mechanisms 
between cells (via cytokines and cytokine receptors) and between cells and 
extracellular matrix (via ECM-glycoproteins and integrins; Jessen and Richardson, 
2002).  
Signal transduction processes after peripheral nerve lesions are well described 
(Gillen et al., 1997; Raivich et al., 1999), yet although injury-induced changes in 
gene expression of many cytokines have been described in this context, much less 
is known about their regulation. It has been suggested that the transcriptional 
activator retinoic acid (RA) might control the expression of signalling molecules in 
the adult nervous system (Mey, 2001). This hypothesis is supported by indirect 
evidence: several nuclear RA-receptors, RA-synthesising enzymes and cellular RA 
binding proteins have been located in the adult central nervous system (CNS; Dev 
et al., 1993), oligodendrocytes synthesise RA in vitro (Mey and Hammelmann, 
2000) and in some cases RA promotes axonal regeneration in vitro (Corcoran and 
Maden, 1999; Corcoran et al., 2000; Mey and Rombach, 1999). In a variety of cell 
culture systems unrelated to the nervous system, RA regulated the expression of 
many intracellular signals which take part in the physiology of nerve regeneration 
(Chang et al., 2000; Choudhury et al., 2000; Mey, 2001). However, no experiments 
have so far been conducted to prove that functional retinoid signalling forms part of 
the traumatic reactions in the nervous system.  
Pursuing the hypothesis that RA serves as a regulator of lesion-induced 
cytokine signalling I investigated the expression of the RA-signalling cascade in 
the PNS and in Schwann cell primary cultures. Taking into account the fact that the 
distribution of retinoic acid is determined by the activity of retinaldehyde 
dehydrogenases, their expression was measured after traumatic injury of rat and 
mouse sciatic nerves. 
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3.1.3. Materials and methods 
Surgical procedures 
Adult male Sprague-Dawley rats (for RT-PCR) and NMRI mice (for in situ 
hybridisation) were used in this study and handled as described in part 2.1.  
   Cell culture 
Primary cultures of Schwann cells were prepared from new-born Sprague-
Dawley rats and processed as described in 2.2. 
Immunocytochemistry 
Sciatic nerves from adult rats were fixed 1 h in cold ethanol, cryoprotected in 
sucrose and cut with a cryostat in 20 µ m longitudinal sections. 
Immunocytochemistry procedures are described in the part 2.3.  
RT-PCR 
Total RNA was isolated using Trizol (Invitrogen), reverse transcribed, and 
cDNA was amplified as described in 2.5. The PCR products were separated by aga-
rose gel electrophoresis and stained with ethidium bromide to verify their expected 
sizes.  
Quantitative PCR 
To quantify the amounts of RALDH-I and RALDH-II mRNA after crush PCRs 
were performed by means of the Roche Light Cycler System using the QuantiTect 
SYBR Green PCR Kit (Qiagen) and Light Cycler Software, Version 3 (Roche) as 
described in 2.6.  
In situ hybridisation 
In order to detect the presence of retinaldehyde dehydrogenases (RALDHs) in 
sciatic nerves of NMRI mice after the injury, in situ hybridisation (ISH) was 
performed according to the protocol described in 2.4. In vitro transcription of insert 
DNA into complementary DIG-labelled RNA riboprobe was done according to the 
scheme listed in 2.4. 
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3.1.4. Results 
The retinoic acid signalling cascade is present in the rat sciatic nerve and in 
Schwann cells in vitro. 
Signal transduction of retinoic acid requires the activation of nuclear receptors 
that act as transcription factors. I analysed their expression with RT-PCR. Genes of 
all known retinoic acid receptors (RARα, −β, −γ) and retinoid X receptors 
(RXRα, −β, −γ) were found to be expressed in rat sciatic nerves (Fig. 3.1.1) and in 
Schwann cells of the primary culture (Fig. 3.1.2). In addition, I detected gene 
products of the cellular retinol binding protein CRBP-I and cellular retinoic acid 
binding proteins CRABP-I and CRABP-II, and of the retinoic acid catabolising en-
zyme CYP26 (it gave a weak but detectable signal). Figs. 3.1.1 and 3.1.2 show the 
amplified fragments. 
 
 
Fig. 3.1.1 The retinoic acid signalling system is present in the rat sciatic nerve. 
Gene expression of retinoid receptors (Aα: RARα, Xα: RXRα etc.), cellular reti-
noid binding proteins (CI: CRBP-I, CaI: CRABP-I, CaII: CRABP-II), aldehyde 
dehydrogenases (R1: RALDH-1, R2: RALDH-2, R3: RALDH-3) and RA degrading 
enzyme CYP26 (c26) are shown with RT-PCR. The molecular weights were consis-
tent with the predicted sizes of all PCR fragments. bp: 100 bp maker, stronger band 
at 600 bp.  
 
Traumatic injury of PNS does not induce changes in RALDH expression. 
The temporal and spatial activity of retinoic acid is thought to be determined by the 
local distribution of RA synthesising aldehyde dehydrogenases (Ross et al., 2000). 
While in mammalian and avian embryos, three enzymes, RALDH-1, -2, and -3, are 
known to oxidise retinaldehyde to RA, only RALDH-1 and -2 have been detected 
after completion of development (Wagner et al., 2002). With RT-PCR I found tran-
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scripts of RALDH-2 as well as of RALDH-1 and RALDH-3 in the intact sciatic 
nerves and 7 days after crush (Fig. 3.1.3).  
 
 
 
 
Fig. 3.1.3 RALDH-1, RALDH-2 and RALDH-3 are expressed in intact and 
lesioned sciatic nerves. Gene expression of RALDHs is shown with RT-PCR for 
crushed (cr) and control (c) sciatic nerves. The molecular weights were consistent 
with the predicted sizes of both PCR fragment: 404 bp for RALDH-1, 443 bp for 
RALDH-2 and 404 bp for RALDH-3. bp: 100 bp maker, stronger band at 600 bp.  
 
The hypothesis of an altered expression of RALDHs after crush injury was 
tested using quantitative PCR on Light Cycler (Roche) and in situ hybridisation. 
Fig. 3.1.2 The retinoic acid 
signalling system is present in 
the Schwann cell primary 
cultures. Gene expression of 
retinoid receptors (Aα: RARα, 
Xα: RXRα etc.), cellular retinoid 
binding proteins (C-I: CRBP-I,  
C-II: CRABP-II), aldehyde 
dehydrogenases (R1: RALDH-1, 
R2: RALDH-2, R3: RALDH-3) 
and of house-keeping gene 
GAPDH) is shown with RT-PCR. 
(0) – RARα amplification of the 
negative control (w/o RT). The 
molecular weights were consis-
tent with the predicted sizes of all 
PCR fragments.  
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Even though the expression of RALDH-1, RALDH-2 and RALDH-3 was shown 
with conventional PCR (Fig. 3.1.3), I could not detect any expression of this 
transcripts with the Light Cycler. Table 3.1. shows all Light Cycler PCR 
parameters tested in this study. For RALDH-2 twelve different primer pairs, five 
MgCl2 concentrations or annealing (AN) temperatures, as well as three different 
tissues were tested to optimise PCR reactions. In many cases irreproducible (*) 
results were obtained. In the case of oligodendrocytes (OLN-93 cell line) none of 
the tested parameters led to amplification, although in these cells the presence of 
RALDH-2 had been confirmed with Western blotting and enzyme assay (Mey and 
Hammelmann, 2000) .     
 
Table 3.1. Light Cycler PCR parameters 
AN temperature [°C] MgCl2 [mM] 
tissue  
45 55 57 58 60 0 2 3 4 5 
primer 
pairs 
result 
(*/-) 
Sciatic nerve  x x x x x x x x x x (*) 
Sch. cells   x   x x x x x x (*) 
OLN-93 x x x x x x x x x x x (-) 
 
The Light Cycler system is developed to use so called “rapid cycle PCR”, in 
which temperature changes occur according to a “kinetic” paradigm. This paradigm 
emphasises temperature transition, thus denaturation and annealing are reduced to 
only few seconds and the temperature may always be changing. Unfortunately, such 
a cycling pattern is not optimal for many genes, which seems to be the case for 
RALDHs. One of the alternative methods for evaluation of gene expression is in 
situ hybridisation (ISH). This technique allows specific nucleic acid sequences to 
be detected in morphologically preserved tissue sections. It requires a riboprobe 
which contains a reporter molecule that can be detected by affinity cytochemistry. 
The riboprobes for RALDH-1 and RALDH-2 used in this study were synthesised in 
co-opertation with Dr. U. Commandeur (Institute of Biology VII, RWTH-Aachen). 
Since vectors with DNA inserts from Mus musculus genome were used, ISH was 
performed with crushed and intact sciatic nerves of NMRI mice. Fourteen pairs of 
crushed and control sciatic nerves were compared during three independent in situ 
hybridisation experiments. Figure 3.1.4 shows representative nerve sections tested 
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for the presence of RALDH-2 in intact and lesioned tissue. For semi-quantification 
of RALDH-1 and RALDH-2 expression the following method was developed: 
Staining intensity of nerves and of the slide background was measured using 
AxioVision Software, Version 3 (Zeiss). From these values a quotient of staining 
intensities was calculated. These quotients were then statistically compared for 
intact and crushed sciatic nerves. For RALDH-1 23 sections of control nerves and 
38 sections of the crushed (7 days) nerves were evaluated. For RALDH-2 24 
sections of control nerves and 56 sections of crushed (7 days) nerves were 
evaluated. 12 mice were used to investigate the regeneration at this point of time. 
For the 24 h only 2 sections (2 mice) were evaluated for both genes.  
 
 
 
Fig. 3.1.4 ISH of RALDH-2 expression after sciatic nerve injury. Riboprobe 
hybridisation of RALDH-2 in the intact sciatic nerve (control) and 7 days after 
lesion. 
 
Figure 3.1.5 shows the development of RALDH-1 and RALDH-2 transcript 
levels 24 h and 7 days after crush lesion. After confirming their normal distribution 
(Shapiro-Wilk W test) the effect of the lesion was tested with ANOVA. An 
apparent up-regulation of both transcripts was not significant either 24 h or 7 days 
after the injury.  
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Fig. 3.1.5 Relative quantification of RALDH-2 mRNA expression. Staining 
intensity in non-injured (control) and lesioned (24 h or 7 days) nerves, black col-
umns: RALDH-2, white columns: RALDH-1, error bars represent standard error of 
mean (SEM). Strength of the staining is calculated in relation to the contralateral 
(control) side. Lesion induced changes in immunoreactivity were not significant 
(ANOVA). 
 
3.1.5. Discussion 
The data obtained in this part of my thesis show the presence of all major 
retinoid signalling molecules in the intact PNS. With RT-PCR I detected the mRNA 
expression of all six retinoid receptors, as well as of retinoic acid synthesising 
enzymes, cellular retinoid binding proteins, retinoid receptors and the catabolising 
enzyme CYP26. Thus, RA can be synthesised in sciatic nerves (suggested by the 
presence of gene transcripts for RALDHs and CRBP-I), transported to the nucleus 
(CRABP-II) and activate gene transcription (RARs and RXRs). Moreover, the 
excess of RA can be compartmentalised (CRABP-I) and catabolysed (CYP26). 
Even though the cells which express retinoid signalling in the sciatic nerve are 
unknown, the presence of all components of this system in primary Schwann cell 
cultures allows the possibility that these cells may by the source and/or putative 
targets of RA signalling.  
These findings open a new field of the possible functions of RA: involvement 
in regeneration processes. Because of its role in neuronal and glial differentiation, 
RA has previously been suggested to regulate gene expression in regenerating 
nerves (Mey, 2001). Besides, as mentioned above, this hypothesis is supported by 
the recent finding of a RA-dependent down-regulation of the gene expression of 
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ciliary neurotrophic factor (CNTF) in Schwann cells (Johann et al., 2003), which is 
similarly happening after nerve injury (Sendtner et al., 1996).   
The local distribution of RA synthesising aldehyde dehydrogenases 
determines the spatial and temporal activity of retinoic acid (Ross et al., 2000). To 
test whether increased expression of RALDH was responsible for the lesion-
induced RA signal I evaluated the mRNA levels of RALDH-1 and RALDH-2 seven 
days after crush injury. Despite an apparent increase in the RALDH-1 and RALDH-
2 signal after in situ hybridisation and RT-PCR, no statistically significant changes 
were observed at the mRNA level. To analyse the protein expression of RALDH-2, 
its immunoreactivity was tested with Western blot and shown to be present, 
however also at this level of expressing, no significant changes after crush (or 
transection) were observed (K. Schrage, Diploma thesis). Using a zymography bio-
assay RA-synthesising activity in cytosolic extracts from the nerves was previously 
investigated. With this test, enzyme activity of RALDH-2 but not of RALDH-1 and 
-3 was detected (Zhelyaznik et al., 2003). The pattern of RALDH-2 staining in 
cryostat sections suggested that this aldehyde dehydrogenase was present in the 
cytosol of Schwann cells because its distribution resembled that of S-100 protein, a 
marker for Schwann cells in the peripheral nerve  (Zhelyaznik et al., 2003). 
Experiments with the Schwann cell cultures also showed the presence of RALDH-2 
immunoreactivity in these cells (J.Mey and K.Schrage, unpublished observations). 
These findings suggested that retinoic acid may be synthesised in sciatic nerves and 
Schwann cells in vitro, but that retinoid signalling may not to be regulated at the 
level of RA-synthesis. This raised the question whether retinoic acid is 
transcriptionally active in sciatic nerve after injury. To monitor the local 
transcriptional activity of RA within the injured sciatic nerve a transgenic mouse 
strain where endogenous RA induces the local expression of β-galactosidase as a 
reporter gene (Rossant et al., 1991) was used. Colorimetric staining for the lacZ 
product indicated regions with local activation of RA response elements (RARE), 
indicative of all-trans RA signalling (Wagner et al., 2000). Whereas in normal, 
non-injured sciatic nerves no β-galactosidase activity was detected whatsoever, a 
crush lesion caused RARE-induced gene expression within 2 days. The staining 
increased with time, reached a maximum 7 days after injury and declined thereafter 
(Zhelyaznik et al., 2003). This activation of RARE-regulated gene expression after 
nerve lesion indicated the participation of RA in traumatic processes following PNS 
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injury, however the mechanisms of this process are still unclear. Obviously the 
expression of other components of RA-system must be studied in future, as well as 
possible biological functions of retinoic acid action after injury. 
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3.2. Activation of retinoic acid signalling after 
sciatic nerve injury: up-regulation of cellular 
retinoid binding proteins 
 
 
 
3.2.1. Abstract 
In mammalian peripheral nerves a crush lesion causes interactions between in-
jured neurons, Schwann cells and hematogenous macrophages that can lead to 
successful axonal regeneration. I suggest that the transcriptional activator retinoic 
acid (RA) takes part in gene regulation after peripheral nerve injury and that RA 
signalling is activated via the cellular retinoic acid binding protein (CRABP)-II and 
cellular retinol binding protein (CRBP)-I. Sciatic nerve crush as well as transection 
resulted in a more than 10-fold up-regulation of CRBP-I, which is thought to facili-
tate the synthesis of RA. Both kinds of injury also caused a 15-fold increase in 
transcript and protein concentration of CRABP-II, a possible mediator of RA 
transfer to its nuclear receptors. Since the transcript and protein levels did not 
decline with time in degenerating nerves compared with regenerating tissue, I 
propose a function of RA during Wallerian degeneration. 
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3.2.2. Introduction 
Retinoic acid (RA) is a transcriptional regulator of gene expression. Its 
intracellular processing is mediated by four binding proteins: cellular retinol 
binding protein (CRBP) types I and II and cellular retinoic acid binding proteins 
(CRABP) types I and II (Marill et al., 2003). After cellular uptake CRBP-I binds 
retinol and is involved in the storage as well as in oxidation of retinol via retinal to 
retinoic acid, reactions catalysed by alcohol dehydrogenases and RALDHs 
(McCaffery and Dräger, 2000; Ross et al., 2000). The role of CRBP-II, which is 
mainly found in the enterocytes of the gut, may be to handle retinoids after dietary 
uptake for further metabolism and transport to the liver (Napoli, 1996). 
Both CRABP-I and CRABP-II have been shown to bind all-trans RA (Marill 
et al., 2003). However, the role of these two proteins is still not quite resolved. 
CRBP-I has been suggested to be involved in the regulation of RA availability for 
nuclear receptors by preventing RA from reaching the nucleus. Thus CRABP-I 
seems to protect cells from excess RA levels, since the CRABP-I/RA complex 
appears to favour RA-catabolism (Dong et al., 1999a). CRABP-II on the other hand 
facilitates the transport of RA to the nucleus, suggesting that it participates in the 
activation of nuclear receptors by RA (Budhu and Noy, 2002). 
It was shown recently that the transcriptional activity of retinoic acid is 
enhanced when it was bound to CRABP-II (Delva et al., 1999; Dong et al., 1999a; 
Nikiforovich and Frieden, 2002), and that CRABP-II can directly co-activate 
RARα/RXRα heterodimers, without engaging the ligand binding domain of 
CRABP-II (Bastie et al., 2001). While RA activates gene expression in the absence 
of CRABP-II (Lampron et al., 1995), the regulation of CRABP-II may be the 
trigger of retinoid signalling under certain circumstances, either by facilitating the 
nuclear transfer of RA or by direct co-activation of retinoid receptors. CRBP-I, 
being an indicator of cells which are able to synthesise RA, may also be important 
in nerve regeneration. By supporting enzymatic oxidation of retinol and retinal the 
elevated concentration of CRBP-I may as well lead to RA increase. Unbound 
CRBP-I (apo-CRBP) inhibits retinol acyltransferase, which esterifies retinol. Some 
pieces of evidence were collected that in the developing mouse central nervous 
system the CRBP-I-expressing cells synthesise and use RA in regulation of their 
own gene transcription (Napoli, 1996). Since some embryonic processes are 
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reactivated during regeneration in the adult, this observation may also apply for the 
regenerating peripheral nervous system.  
Taking into account my previous studies, that show RA-system presence in the 
peripheral nervous system, I propose that retinoid signalling is activated by a 
peripheral nerve lesion via the up-regulation of the cellular retinoid binding 
proteins CRBP-I and CRABP-II.  
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3.2.3. Materials and methods 
Surgical procedures 
Adult male Sprague-Dawley rats were used in this study and handled as 
described in part 2.1.  
RT-PCR 
Total RNA was isolated using Trizol (Invitrogen), reverse transcribed and 
cDNA was amplified with PCR as described in 2.5. The PCR products were sepa-
rated by agarose gel electrophoresis and stained with ethidium bromide to verify 
their expected sizes.  
Quantitative PCR 
To quantify the amounts of CRBP-I and CRABP-II mRNA after crush or 
transection, PCRs were performed by means of the Roche Light Cycler System 
using the QuantiTect SYBR Green PCR Kit (Qiagen) and Light Cycler Software, 
Version 3 as described in 2.6. The PCR efficiencies (amplification per cycle) were 
for GAPDH 1.65; for -actin, CRBP-I and CRABP-II 2.00. For every condition 
three to five independent Light Cycler experiments with pairs of crushed and 
control sciatic nerves and L4-L6 DRGs ipsilateral and contralateral to the lesion 
were performed and statistically analysed with Jmp software (SAS institute). For 
this, logarithms of the mRNA ratios of lesioned nerves to control nerves were cal-
culated and corrected for differences in the extract concentrations based on the 
GAPDH or -actin analysis as described in 2.6. After confirming their normal 
distribution (Shapiro-Wilk W test) data were tested with ANOVA and Dunnett’s 
test. The identity of PCR products was confirmed with melting curve analysis and 
agarose gel electrophoresis. In addition, the amplified cDNA fragments of CRBP-I 
and CRABP-II were eluted from the agarose, cloned (TOPO-TA cloning; 
Invitrogen) and sequenced. 
Western blotting 
For immunoblotting, nerves were sonicated in hypotonic buffer with a mix of 
protease inhibitors as described in 2.7. Strength of immunoreactivity was always 
expressed in relation to the contralateral side, set at 100%. From immunoreactivity 
data the logarithms of the signal ratios of lesioned nerves to control nerves were 
calculated and tested with ANOVA and Dunnett’s test. 
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3.2.4. Results 
Nerve lesions cause up-regulation of CRBP-I and CRABP-II  
Taking into account the rather stagnant level of RALDH-2, I surmised that the 
transcriptional effect of RA may be triggered through up-regulation of CRBP-I and 
CRABP-II. In order to investigate this, their mRNA concentrations were measured 
with quantitative RT-PCR (Light Cycler, Roche). The expression of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) or -actin was quantified as positive 
control in every experiment. Dilution series of cDNA extracts were used to de-
termine PCR efficiencies for each primer pair.  
Fig. 3.2.1a shows representative amplification curves where 7 days after nerve 
crush the expression of CRBP-I as well as of CRABP-II was increased compared to 
GAPDH expression. At this point in time, axonal regeneration occurred within the 
nerve segment. In order to control the identity of PCR amplificates, melting curve 
analysis and agarose gel electrophoresis of PCR products were performed after 
every experiment (Fig. 3.2.1b, c). In addition, amplified fragments were cloned and 
sequenced, and the obtained sequences were identical to the predicted sequences of 
the target genes. Fig. 3.2.2 shows the development of CRBP-I and CRABP-II 
transcript levels up to 14 days after sciatic nerve lesion. Gene expression was 
investigated in the nerve segment 1 cm distal from the lesion site.  
The up-regulation of CRBP-I and CRABP-II gene expression started during 
the first 24 hrs after a nerve crush and remained above control levels for at least 2 
weeks (ANOVA, p<0.05). For both genes, a more than 10-fold increase was seen 2 
days after a crush lesion (first maximum; Dunnett’s test, CRBP-I p<0.05, CRABP-
II p<0.01), CRABP-II reached a second maximum again after 7 days (p<0.01). 
Then, at two weeks after a crush, gene expression decreased in comparison with the 
situation after the first week when axonal regeneration occurred in the nerve 
segment. After 14 days the mRNA levels of CRBP-I were not significantly higher 
than in non-injured control nerves.  
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Fig. 3.2.1 Up-regulation of CRBP-I and CRABP-II mRNA after sciatic nerve 
injury, quantitative RT-PCR. a Representative amplification curves with primers 
for CRBP-I and CRABP-II. Broken lines represent results for sciatic nerves 7 days 
after nerve crush, continuous lines for non-injured nerves. The horizontal dashed 
line indicates background level of SYBR Green fluorescence which was used for 
quantification. While no lesion-induced change is observed for the concentration of 
GAPDH, the left shift of crossing points after crush injury indicates higher 
transcript concentrations of CRBP-I and CRABP-II. After all quantitative RT-PCR 
runs the amplified fragments were characterised b by their melting curves, and c 
with agarose gel electrophoresis. Expected fragment sizes were 408 bp (CRABP-II) 
and 409 bp (CRBP-I). Three independent experiments are shown with amplified 
fragments from nerves 7 days after crush (7d) and the contralateral controls (c), 
PCR amplification without reverse transcription is marked 0. The three distinct 
marker bands have 400, 300 and 200 bp. 
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Fig 3.2.2 Relative quantification of mRNA concentrations. Data for the first 2 
weeks after sciatic nerve lesions, normalised to transcript levels in the 
contralateral, non-injured nerves. Analyses were performed after sciatic nerve 
crush (black columns) and after complete transections (grey columns). Error bars 
indicate 95% confidence intervals. Analysis of variance showed a significant effect 
of both kinds of lesion on CRBP-I and CRABP-II expression (p<0.05). Asterisks 
indicate significant differences compared to the non-lesioned control (n=5 for the 
point in time 7 days, n=3 for all others; Dunnett’s test, * p<0.05, ** p<0.01). 
 
Sciatic nerve crush causes a transient and nerve transection a lasting 
increase of cellular retinoid binding proteins  
In addition to crush lesions I also performed nerve transections to cause 
Wallerian degeneration, but prevented axonal regeneration into the distal nerve seg-
ment. While in these experiments the expression of CRBP-I and CRABP-II rose 
similarly to the regeneration paradigm, they did not decline during the second week 
in the nerve segment distal to the lesion, such that after 14 days transcript levels 
remained higher than when regeneration occurred (Fig. 3.2.2). Same RT-PCR ex-
periments were performed for L4-L6 dorsal root ganglia (DRG) ipsilateral and 
contralateral to the crushed nerve. During the first week after injury I found a 2-
fold to 3-fold increase in gene expression in DRG, yet these effects were not 
significant. The maximum mRNA increases compared to the contralateral side were 
for CRBP-I: 2.2 (n = 4, SD = 2.1) and for CRABP-II: 3.2 (n = 4, SD = 2.4).  
For the assessment of CRABP-II immunoreactivity in the sciatic nerves I used 
a monoclonal antibody kindly provided by Pierre Chambon (see Tab. 2.1). 
Consistent with results on gene expression, the protein levels of the retinoic acid 
binding protein increased 2 days after a crush lesion, reached a maximum after 7 
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days and were lower again at 14 days, when axonal regeneration had occurred in 
the nerve segment (Fig. 3.2.3a). In case of nerve transection I also found CRABP-II 
increase in the distal nerve stump, which initially paralleled the development in the 
crush model. As axonal regeneration was not possible in the distal stump, CRABP-
II remained high for at least two weeks after the lesion (Fig. 3.2.3b). Injury-
induced changes in protein concentration were significant in both paradigms 
(ANOVA p<0.05). In order to investigate local CRABP-II distribution, 11 pieces of 
sciatic nerve 2.5 mm each were obtained. CRABP-II immunoreactiviy reached its 
highest level around and distal to the site of the lesion (Fig. 3.2.4). 
 
 
 
 
 
 
 
 
Fig. 3.2.3 Increase of CRABP-II 
immunoreactivity after sciatic nerve 
crush and transection. a CRABP-II 
signalling the intact sciatic nerve and 
distal to the site of crush injury and 
transection, immunoblots, 10 µ g protein 
per lane. Indicated are time intervals 
after injury when nerves were prepared 
and proteins extracted. b Quantification 
of the immunoreactivity signal. Effects 
of nerve crush and transection on 
CRABP-II immunoreactivity were 
significant (n=3, ANOVA p<0,05), and 
signal strength were compared with 
non-injured controls using Dunnett’s 
test (error bars show 95% confidence 
interval, *p<0,05; **p<0,01). 
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3.2.5. Discussion 
Although RALDH transcripts and immunoreactivity in my previous study 
were present in the intact PNS, transcriptional RARE activation was apparent in the 
injured nerves. In vitro experiments using RA-sensitive reporter cells indicate that 
rat sciatic nerves do not release RA, suggesting that the activation of RARE-
regulated genes is confined to the nerve itself (Zhelyaznik et al., 2003). Additional 
mechanisms of control may therefore be at work. These could include RA 
degrading enzymes (Mey, 2001; Swindell et al., 1999; Mey et al., 2001), orphan 
receptors like COUP-TFII that interfere with DNA-binding of the retinoid receptors 
(McCaffery et al., 1999), retinoid receptors themselves or cellular retinoid binding 
proteins. 
In this part of my thesis I showed that sciatic nerve lesions induced up-
regulation of cellular retinol binding protein (CRBP)-I and cellular retinoic acid 
binding protein (CRABP)-II. Relative quantification of obtained gene expression of 
CRABP-II is high already 24 hours after lesion and reaches its maximum on the 
second day. This was also observed for CRBP-I. Then gene expression decreased 
when the regeneration has occurred. When no regeneration was allowed (after 
sciatic nerve transection) the expression of CRBP-I and CRABP-II rose similar to 
regeneration paradigm, but did not decline during the second week.  
In response to nerve injury it is therefore possible that RA is synthesised due 
to RALDH-2 activity in the presence of increased CRBP-I. The up-regulation of 
CRABP-II will then facilitate RARE-regulated gene activation. Many genes related 
Fig. 3.2.4 CRABP-II signal in 2.5 
mm nerve sections. Proximal and 
distal parts to the site of crush 
injury, 7 days after the lesion, n=1. 
X-axis indicates distance from the 
lesion (white columns: proximal, 
grey columns: distal), y-axis shows 
relative strength of the immuno-
reactive signal in Western blots. 
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to the regulation of Wallerian degeneration and peripheral nerve regeneration count 
among the targets of RA. They include neurotrophin receptors, neuropoietic 
cytokines, TGFβ1-3 and various transcription factors (Mey, 2001). In contrast to 
the drastic increase of CRABP-II and CRBP-I expression in injured sciatic nerves, 
there was only a slight and non-significant up-regulation of the two binding 
proteins in L4-L6 DRGs, suggesting that the nerve cells are possibly neither the 
origin of RA signalling nor its target. However one can not exclude that RA, 
enzymes or binding proteins in injured nerves may be retrogradely transported to 
the neuronal cell bodies.  
Gene expression analysis as well as the data on protein immunoreactivity 
suggest that CRBP-I and CRABP-II activity decreases subsequent to axonal 
regeneration. Their up-regulation was however observed in degenerating nerves 
severed from the central neuronal cell bodies, and here transcript and protein 
expression remained higher even after 2 weeks. This observation suggests the 
involvement of retinoic acid signalling in Wallerian degeneration – the process 
which initiates axonal regeneration (Fawcett and Keynes, 1990). Additional 
evidence supporting this hypothesis was recently obtained in our laboratory: 
retinoic acid induced the down-regulation of ciliary neurotrophic factor (CNTF) in 
Schwann cells from the primary culture, similar to the development during 
Wallerian degeneration (Sendtner et al., 1996; Curtis et al., 1993). 
My present data, showing strong and significant up-regulation of CRBP-I and 
CRABP-II after sciatic nerve lesions in connection with the activation of an RARE-
reporter gene in vivo (Zhelyaznik et al., 2003), support the hypothesis of retinoic 
acid involvement in gene regulation after nerve injury. However, additional levels 
of RA-signalling regulation can not be excluded. Thus the cellular levels of retinoid 
receptors must be studied next. 
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3.3. Retinoic acid receptors and retinoid X 
receptors are activated after sciatic nerve injury 
 
 
 
3.3.1. Abstract 
As it becomes clear from 3.1 and 3.2, the retinoic acid system is present in 
peripheral nervous system. There it is possibly taking part in regeneration since all 
necessary components of RA signalling pathway are detectable in sciatic nerves, 
and the expression and protein levels of cellular retinoid binding proteins CRBP-I 
and CRABP-II are strongly up-regulated by the lesion. Since the effect of RA is 
mediated via the ligand-activated transcription factors retinoic acid receptors 
(RAR) and retinoid X receptors (RXR), the levels of these were measured in the 
present study with RT-PCR and immunoblotting. It was shown that the 
immunoreactivity of RARα was about 4 times, of RXRα about 2 times and of 
RXRβ about 1.5 times higher than in unlesioned tissue. Thus, retinoid receptors too 
are affected by the injury. In addition, Schwann cells were identified as possible 
targets of RA transcriptional effects in sciatic nerves because they express all six 
retinoid receptors, which was shown with immunocytochemistry analysis and, 
according to RT-PCR data, the expression of RARβ and RARγ was found to be up-
regulated after RA treatment.  
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3.3.2. Introduction 
The retinoid signal is transduced by two families of nuclear receptors, the 
retinoic acid receptor (RAR) family comprising 3 genes: RARα, RARβ, RARγ, and 
the retinoid X receptor (RXR) family also including 3 genes, RXRα, RXRβ and 
RXRγ (Mangelsdorf and Evans, 1992; Chambon, 1996). Due to alternative splicing 
and differential promoter usage there are also several isoforms of each family 
member. RARs and RXRs belong to the superfamily of nuclear hormone receptors 
and act as ligand activated transcriptional factors. The natural ligands for the RARs 
are all-trans-retinoic acid and its stereo isomer 9-cis-RA, whereas RXRs are 
activated by the natural ligand 9-cis-RA only (Mangelsdorf and Evans, 1992; Marill 
et al., 2003; Chambon, 1996). Five types of retinoic acid response elements 
(RARE) were found on RA-regulated genes, they consist of inverted (palindrome) 
base repetitions (direct repeats, DR) with 1-5 nucleotides as a spacer. The most 
frequent are DR-5 of the type, which are present in RARβ2 and RARα2 genes. 
Other types are less common, for instance DR-1 and DR-2 were found in CRABP-II 
and CRBP-I genes respectively (Marill et al., 2003; Chambon, 1996). While RAR 
must bind to RXR and thus can act only as heterodimer, RXR can act as homodimer 
via the retinoid X response element (RXRE, DR-1) and also as heterodimer with 
several nuclear receptors, e.g. thyroid hormone receptor, vitamin D receptor, or 
orphan receptor COUP (Mangelsdorf and Evans, 1992; Marill et al., 2003; 
Chambon, 1996), indicating a second retinoid signalling pathway. This ability of 
RXR to interact with receptors responsive to a variety of ligands establishes a 
central role for RXR in modulating multiple hormone pathways.  
The activity of RARs may be modulated by the nuclear transcription factor 
AP-1, the complex formed by the proto-oncoproteins Jun and Fos, whose activity is 
stimulated by tumour promoters and growth factors. Agents which stimulate AP-1 
synthesis block the action of RA. Reciprocally, RA treatment is capable of 
influencing the action of AP-1. Possibly, a cross-coupling mechanism is involved, 
by which retinoid and other nuclear receptors can regulate the function of other 
transcription factors through both DNA-binding and DNA-independent protein-
protein interactions (Mangelsdorf and Evans, 1992). 
The examination of homozygous mutant mice generated by targeted disruption 
of RAR or RXR genes in embryonic stem cells showed that RARα-/- mice die early 
postnatally due to testis degeneration. RXRα-/- mutant mice die as embryos 
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because these receptors are required for heart development. RARβ null-mutants 
appear completely normal, and RARγ, RXRβ and RXRγ have subtle defects 
mimicking a mild form of the fetal vitamin A deficiency syndrome (Ross et al., 
2000). These results suggest a high degree of functional redundancy among retinoid 
receptors. However, double mutants carrying two RAR defects die either in utero or 
shortly after birth, showing most symptoms of severe fetal vitamin A deficiency 
(Roos et al., 1998). These studies demonstrate that RARs are essential for 
vertebrate development.  
The pleiotropic effects of retinoids might be explained in part by the patterns 
of expression of various RAR and RXR genes. In adult mammals RARα and 
RXRβ  are widespread, RARβ  is specifically expressed in muscle and prostate, 
RARγ in skin and lung, RXRα in liver, skin and kidney, RXRγ in muscle and heart 
(Mangelsdorf and Evans, 1992; Sugawara et al., 1997). Less is known about the 
adult nervous system. The functions of the RA-system were studied in adult CNS 
(Denisenko-Nehrbass et al., 2000; Weiler et al., 2000; Zhang and McMahon, 2001) 
and the expression of retinoid receptors was shown for different brain regions 
(Cullingford et al., 1998; Zetterström et al., 1999). The aim of this study was 
therefore to investigate the expression of RARs and RXRs in the PNS and compare 
their expression after peripheral nerve lesion. 
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3.3.3. Materials and methods 
Cell culture 
Primary cultures of Schwann cells were prepared from new-born Sprague-
Dawley rats and processed as described in 2.2. 
Surgical procedures 
Adult male Sprague-Dawley rats were used in this study and handled as 
described in part 2.1.  
Immunocytochemistry 
Sciatic nerves were fixed in ethanol and treated as described in 2.3. Primary 
antisera against S-100, RARα, -β, -γ and RXRα, -β, -γ were detected with 
peroxidase-conjugated secondary antibodies and the avidin-biotin-peroxidase 
method as described in 3.3.   
RT-PCR 
Total RNA was isolated using Trizol (Invitrogen) and reverse transcribed to 
obtain cDNA, which was amplified with PCR as described in 2.5. The PCR 
products were separated by agarose gel electrophoresis and stained with ethidium 
bromide to verify their expected sizes. From fluorescence intensity data the 
logarithms of the signal ratios of lesioned nerves to control nerves were calculated 
and tested with ANOVA and Dunnett’s test. 
  
Western blotting 
For immunoblotting, nerves were sonicated in hypotonic buffer with a mix of 
protease inhibitors as described in 2.7. Strength of immunoreactivity was always 
expressed in relation to the contralateral side, set at 100%. From immunoreactivity 
data the logarithms of the signal ratios of lesioned nerves to control nerves were 
calculated and tested with ANOVA and Dunnett’s test. 
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3.3.4. Results 
Retinoid receptors are present in PNS and are probably localised to 
Schwann cells 
As shown in part 3.1, sciatic nerves express all known retinoic acid receptors 
(RARα, -β, -γ) and retinoid X receptors (RXRα, -β, -γ; Fig. 3.1.1), however, their 
cellular location has not yet been determined. In this study, immunocytochemistry 
analysis was performed and the cellular localisation was investigated. All 
antibodies and working dilutions used are listed in Tab. 2.1. The positive staining 
for RARα, -β, -γ (Fig. 3.3.1) and RXRα, -β, -γ in cryostat sections suggested that 
they were present in sciatic nerves, however their localisation was not determined 
due to the low resolution of the light microscopy method. The positive control was 
done using antibody against S-100 protein, a marker for Schwann cells in the 
peripheral nerve.      
  
Fig. 3.3.1 Immunostai-
ning of retinoid receptors 
distribution in rat sciatic 
nerve.  
Longitudinal cryostat 
sections of nerves: 
negative control, S-100, 
RARα, RARβ,  RARγ, 
RXRα,  RXRβ, RXRγ. 
The immunostaining of 
retinoid receptors 
resembled that of S-100 – 
a marker of Schwann cells 
in the peripheral nerve, 
scale bar 100µ m.  
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Ligand stimulated transcriptional factors retinoic acid and retinoid X 
receptors are activated after the injury 
The activation of retinoic acid receptors after the lesion may be another key 
regulatory factor of retinoic acid action. In order to investigate their expression I 
performed semi-quantitative Western blotting and PCR analyses. For the 
assessment of RARα, -β, -γ and RXRα, -β, -γ immunoreactivity I used commercial 
antibodies, which are listed in Tab. 2.1.  The loading of proteins in each gel slot 
was checked by evaluating Ponceau-S staining of the blot (Fig. 3.3.2b). For gene 
expression the levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 
tested as a positive control for the same cDNA concentration (Fig. 3.3.4g). 
Comparing crushed (7 days post lesion) and intact sciatic nerves I found a strong 
and highly significant up-regulation of RARα immunoreactivity and the more 
moderate but still significant up-regulation of RXRα and RXRβ (Fig. 3.3.2a, c).  
 
  
Fig. 3.3.2 Immuno-
reactivity of RARα, RXRα 
and RXRβ after sciatic 
nerve injury. a Western 
blots, 15 µ g protein per 
lane. Immunoreactivity in 
the intact nerves (C1-3) and 
after a crush lesion (Cr1-3). 
b The equal loading of all 
slotst was verified with 
Ponceau-S staining. c 
Relative quantification of 
immunoreactivity of all 
retinoid receptors (see also 
Fig. 3.3.3). Strength of 
immunoreactivity is ex-
pressed in relation to the 
contralateral side (control)  
Error bars indicate stan-
dard error of mean. 
Asterisks indicate signi-
ficant differences compared 
to the nonlesioned control 
(n=3, ANOVA p<0.05; 
Dunnett’s test *p<0.05; 
**p<0.01; ***p<0.001)   
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The quantification of the immunoblots is presented in Fig. 3.3.2c. 
Immunoreactivity levels of RARβ (Fig. 3.3.3a) and RXRγ (Fig. 3.3.3c) were not 
statistically different from control, while the staining of RARγ (Fig. 3.3.3b) was 
present at very low levels, which was below the sensitivity of the image detection 
system.  
 
 
 
On the mRNA levels, the increase of gene transcripts was also apparent (Fig. 
3.3.4). In these experiments semi-quantification was performed using the same 
analysing software as for immunoreactivity, but this time with ethidium bromide 
signals in agarose gels, run subsequently to conventional PCR. Seven days after 
sciatic nerve crush lesion elevated levels of gene expression of RARα, 
RARβ, RARγ and RXRα were detected (ANOVA, p<0.05). For RXRβ and RXRγ no 
significant changes were observed. Thus at least two functional heterodimers 
(concluded from up-regulated immunoreactivity) of RARα/RXRα and RARα/RXRβ 
may be triggered by the injury. The up-regulation of RARβ was not as prominent 
and significant only on the level of the gene transcript. 
 
 
Fig. 3.3.3 
Immunoreactivity of 
RARβ, RARγ and RXRγ 
after sciatic nerve injury. 
a RARβ, b RARγ,  c RXRγ  
Western blots, 15 µ g pro-
tein pro lane. Immuno-
reactivity in the intact 
nerves (C1-3) and 7 days 
after crush lesion (Cr1-3), 
n=3. Proteins extracted 
from adult retina were 
used as a positive control 
for ECL. Band’s shift in c 
is due to the experimental 
artefact.  
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Fig. 3.3.4 Sciatic nerve lesion induces activation of retinoid receptors. a RARα, 
b RARβ, c RARγ, d RXRα, e RXRβ, f RXRγ,  g GAPDH. Three independent 
experiments are shown for each receptor. Molecular weight marker at 100 bp 
(bottom band), 200 bp, 300 bp etc. Stronger band at 600 bp. The molecular weights 
were consistent with the predicted sizes of all PCR fragments. h Relative 
quantification of mRNA concentrations. Strength of fluorescence is expressed in 
relation to the contralateral side (control) and corrected for the expression of 
GAPDH for each sample. Error bars indicate standard error of mean. Asterisks 
indicate significant differences compared to the non-lesioned control (n=3, ANOVA 
p<0.05, Dunnett’s test *p<0.05; **p<0.01)   
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Retinoic acid autoregulates mRNA expression of its own receptors in 
Schwann cells in vitro. 
One mechanism by which RA may co-ordinate complex gene expression is through 
the direct autoregulation of the retinoid receptors themselves (Mangelsdorf and 
Evans, 1992). To test whether it is the case in PNS, Schwann cell primary cultures 
were used.  
Previously I have shown the expression of all six retinoid receptors in 
Schwann cells in vitro (Fig 3.1.2). To investigate dose-dependent effects of RA, the 
cultures were exposed to 1, 10 and 100 nM all-trans RA for 24 hrs, and the mRNA 
expression of RARα, -β, -γ and RXRα, -β, -γ was analysed with PCR. Control cells 
were treated with DMSO.  
While the expression of GAPDH was constant for RA-treated and control 
cells, the expression of RARβ and RARγ was induced in RA-treated cells. The 
expression of RARα, RXRα, RXRβ and RXRγ was not changed even by the highest 
dose of retinoic acid (Fig 3.3.5). This experiment was repeated only once. 
 
3.3.5 Discussion 
This part of my work was devoted to the question whether retinoic acid 
receptors and retinoid X receptors are regulated by sciatic nerve injury. In part 3.1. 
of my thesis I showed the presence of all six receptors in sciatic nerve, however, 
their cellular localisation remained unclear. In this study I performed 
immunocytochemistry analysis in order to show the possible localisation of the 
receptors. However, the differential interference contrast light microscopy method 
can not provide the resolution to qualify the staining obtained. Obviously, further 
experiments using electron microscopy must be performed. My previous 
experiments suggest, however, that the staining is localised to the Schwann cells, 
since Schwann cells express retinoid receptors (see part 3.1.) and are immuno-
positive for all RARs and RXRs (J. Mey and K.Schrage, unpublished observations) 
in vitro.  
To evaluate the possible changes in gene and protein levels, crush lesions were 
again performed to the sciatic nerves of adult rats and the expressions measured 
with PCR and Western blot. Discrepancies at these two expression levels are not 
infrequent, which is apparent in my data as well.  
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Fig. 3.3.5 RA-dependent activation of retinoid receptors. a RARβ, b RARγ, c 
RXRβ, d RXRα, e RARα, f RXRγ, g GAPDH. Cells were treated 24 h with all-trans 
RA, concentrations in nM; bp: molecular weight marker at 100 bp (bottom band), 
200 bp, 300 bp etc. The molecular weights were consistent with the predicted sizes 
of all PCR fragments. h Relative quantification of PCR results. Strength of 
fluorescence is expressed in relation to the control (DMSO-treated cells) and 
corrected for the expression of GAPDH for each sample, n=1.     
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At the mRNA level all three RAR receptors and RXRα are significantly up-
regulated, while the immunoreactivity of only RARα, but of two RXRs: RXRα and 
RXRβ is positively regulated. These findings suggest that not all elevated genes are 
translated into comparable elevated levels of protein. However the up-regulated 
levels of at least two functional heterodimers: RARα/RXRα and RARα/RXRβ may 
be generated in cells of regenerating sciatic nerves, enabling more retinoic acid to 
propagate its transcriptional effects.   
One mechanism by which RA may regulate gene expression is through the 
direct autoregulation of the retinoid receptors (Mangelsdorf and Evans, 1992). 
According to my data, the expression of RARβ and RARγ is up-regulated by 
retinoic acid treatment in Schwann cells. This effect of RA could be both direct and 
via additional intermediate gene activation, because only RARβ of these two 
contains RA response elements in its promoter (Mangelsdorf and Evans, 1992). The 
effect of RA on its nuclear receptors is dose-dependent, the highest dose of 100 nM 
induced the most potent expression of RARβ and RARγ. As for the biological 
meaning of such regulation, RA may mediate its own positive feedback.  
The implication of the RA-system in regeneration was discussed in the 
previous parts (3.1-3.2). RA is able to induce regeneration in the developing CNS 
and in the CNS in vitro (Corcoran and Maden, 1999; Corcoran et al., 2000; 
Corcoran et al., 2002; Mey and Rombach, 1999) and activate genes in cell cultures 
unrelated to the nervous system (Chang et al., 2000; Choudhury et al., 2000; Mey, 
2001). However, when Corcoran and Maden (1999) introduced RA into the lesioned 
adult CNS no regeneration was induced. A possible explanation of this phenomenon 
is that during transition from embryo to adulthood some or all of the transducers of 
the RA signal may be permanently shut down by transcriptional inactivation. The 
mechanism of retinoid receptor transcriptional inactivation is known. It involves 
histone deacetylase (HDAC)-containing complexes that are tethered through co-
repressors or a silencing mediator to retinoid and thyroid hormone receptors 
thereby inhibiting their functions (Marill et al., 2003).  
On the contrary, axons in the adult PNS are able to regenerate and all 
components of retinoid signalling are present in this tissue. When at first proposing 
a role of retinoic acid in PNS-regeneration, the RA synthesising enzymes seemed to 
be the proper candidates for the regulation of RA availability. However, an up-
regulation of RALDH was not detected after sciatic nerve crush injury (Zhelyaznik 
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et al., 2003). What is more, the application of excess RA (Maden and Hind, 2003), 
which should have overcome the requirement of the RA-synthesising enzymes, did 
not induce neurite outgrowth. Thus RALDH is not the most important key regulator 
in either CNS or PNS regeneration. Other possible key molecules in RA signalling 
activation are cellular binding proteins. CRBP-I is crucial for the RA synthesis 
(Napoli, 1996) and CRABP-II, being able to bring RA to the nuclear receptors, is 
the co-activator of transcription (Budhu and Noy, 2002). Their silencing in adult 
CNS might be one of the explanations of regenerative failure. As shown in part 3.2, 
I showed indeed a strong and significant up-regulation of CRBP-I and CRABP-II 
following peripheral nerve injury (Zhelyaznik et al., 2003). Even though there was 
a report that CRABP-II alone is able to activate RARα/RXRα heterodimers (Bastie, 
2001), it was proved to be insufficient to elicit a transcriptional effect of RA, even 
when excessive RA was available for the cells (Budhu and Noy, 2002). Thus the 
regulation of the nuclear receptors, which are necessary for RA transcriptional 
activity, seems to be  another key process. Performing several in vitro studies, 
Corcoran and Maden (2002) have shown that one of the retinoic acid receptors – 
RARβ2 – is the essential transducer of the RA signal in cultured spinal cords. After 
RARβ2 vector introduction many neurites extended from the explanted adult spinal 
cords in both mouse and rat in vivo. No neurites were observed in several control 
experiments where the cords were transfected with either LacZ or the RARβ4 
isoform, which confirmed the authors’ hypothesis of a specific RARβ2 
involvement. In addition, an RARβ agonist rather than an RARα or RARγ agonist 
specifically induced neurite outgrowth from embryonic neurons (Corcoran and 
Maden, 1999; Corcoran et al., 2000). Even though, one can not exclude that some 
other of the receptors and their splicing isoforms also participate in regeneration. In 
the regenerating PNS the expression of RARα, RXRα and RXRβ is up-regulated, 
while the levels of the other three receptors, including RARβ are unaltered. 
However, high levels of RARβ transcript and protein were expressed at all times, 
and I can not completely rule out that the expression of RARβ isoform 2 is 
regulated.   
Nevertheless, the elevated expression of retinoid receptors in the present study 
can be considered as a specific physiological response of the PNS to injury. This 
additionally supports the proposed role of retinoic acid in regenerating peripheral 
nerves. Further, my finding of a different pattern of receptor expression in the PNS 
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compared to the report of Corcoran and Maden (Corcoran et al., 2000) suggests that 
retinoic acid may take part in regeneration of CNS and PNS via different nuclear 
receptors, which will probably activate different downstream signalling.  
In the future, more detailed comparison of retinoid signalling in PNS and CNS 
must be performed. For instance, the comparison of transcriptional activity of RA 
within the injured sciatic nerve and spinal cord can be done. The expression of 
cellular retinoid binding proteins should also be evaluated, as well as the cellular 
localisation of the RA-system. Further experiments with CRABP-II-/-, RARβ-/- and 
RXRβ-/- mutant mice will clear the possible physiological roles of these three 
molecules in the regeneration processes. The experiments in this direction are 
already being performed in our laboratory. Their results will enable the more 
concrete speculations about the functional relevance of retinoic acid in these two 
systems. Further on, the biological functions of retinoids – the activation of 
downstream gene signalling – must be studied.  
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3.4. Retinoic acid reinforces the expression of 
erbB3 in Schwann cells 
 
 
 
3.4.1. Abstract 
In the peripheral nervous system neuregulins regulate Schwann cell 
proliferation, Wallerian degeneration and development of neuromuscular junctions. 
Retinoic acid (RA) is a possible regulator of neuregulin receptors because it 
interacts with the neuregulin pathway in breast cancer models. It was  discovered 
that the retinoid signalling system is activated after sciatic nerve injury. In light of 
these data I investigated the effect of retinoic acid on the expression of neuregulin 
receptors in Schwann cell primary cultures. Transcripts of the erbB2 tyrosine 
kinase and the erbB3 receptor were detected. In order to investigate dose-dependent 
effects of RA, cultures were exposed to 0.1, 1, 10, 100 and 1000 nM all-trans RA 
for 24 hrs, and the mRNA expression of erbB2 and erbB3 was analyzed with 
quantitative RT-PCR. While RA exerted only a non-significant effect on erbB2 
expression, concentrations of 0.1 to 10 nM RA induced a 4- to 5-fold significant 
up-regulation of erbB3. The transcriptional effect on this receptor was confirmed 
on the protein level with Western blotting experiments. These results indicating a 
possible interaction of RA and β-NRG-1/erbB signalling in the peripheral nervous 
system suggest a biological function of retinoic acid signalling after peripheral 
nerve injury. 
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3.4.2. Introduction 
Neuregulins (NRGs) belong to the family of multipotent growth-promoting 
peptides known to be important in neural and mesenchymal tissue development. In 
the peripheral nervous system (PNS) they are crucial for a number of processes 
including Schwann cell proliferation (Jessen and Mirsky, 1999; Cheng et al., 1998), 
Wallerian degeneration (Kim et al., 2002) and development of neuromuscular 
junctions (Noll and Miller, 1994). So far, four genes are known to encode members 
of the neuregulin family: NRG-1, NRG-2, NRG-3 and NRG-4 (Noll and Miller, 
1994; Falls, 2003). All of them bind preferentially to the receptors erbB3 and 
erbB4. ErbB3 has a high ligand-binding affinity but only impaired kinase activity 
due to substitutions in critical residues of its catalytic domain (Citri et al., 2003). 
ErbB3 and erbB4 receptors form heterodimers by recruiting either erbB1 or erbB2 
tyrosine kinase co-receptors to propagate signalling (Wiley, 2003).  
Among the four neuregulins, β-Neuregulin-1 (β-NRG-1) was initially found to 
function in the regulation of nicotinic acetylcholine receptor transcription at the 
neuromuscular junction (Falls, 2003; Fischbach, 1997), hence it is also referred to 
as ARIA (acetylcholine receptor inducing activity). The functions of β-NRG-1 also 
include regulation of early cell fate determination, differentiation, migration and 
survival of satellite cells, Schwann cells and oligodendrocytes (Buonanno and 
Fischbach, 2001).  
Recent data indicate a functional role of β-NRG-1 after peripheral nerve 
injury. At the neuromuscular junction, β-NRG-1 regulates the expression of 
acetylcholine receptors, thereby controlling the specificity of reinnervation after 
nerve injury (Noll and Miller, 1994). Along the nerve, β-NRG-1, released from 
injured axons promotes Schwann cell proliferation during regeneration (Caroll et 
al., 1997). This cytokine, as well as the expression of its receptors quickly respond 
to the injury. Within one hour after nerve transection, the NRG receptor erbB2 is 
selectively activated at the site of injury as are its downstream signals, including 
immediate-early genes. Based on these data Kim and co-workers (Kim et al., 2002) 
suggested that neuregulin signalling triggers Wallerian degeneration in the adult 
PNS. In addition, the expression of erbB2 and erbB3 genes and protein increases 
strongly after sciatic nerve injury (Caroll et al., 1997). This now raises the question 
about the causes of altered β-NRG-1 signalling and of the regulation of 
erbB2/erbB3 expression. 
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One possible regulator is the transcriptional activator retinoic acid (RA) 
because it interacts with the neuregulin pathway in breast cancer models 
(Offterdinger et al., 2003; Offterdinger et al., 1998; Tari et al., 2002; Martin-
Subero et al., 2001). RA has therapeutic value for the treatment of breast cancer. It 
is known to inhibit chemically induced cancerogenesis in vivo and is anti-
proliferative in vitro, where RA can act as a repressor of neuregulin/erbB 
expression (Offterdinger et al., 1998; Tari et al., 2002; Martin-Subero et al., 2001). 
Since the discovery of the retinoid signalling system activation after sciatic 
nerve injury, the question of its biological meaning has remained unanswered. The 
pattern of up-regulation of cellular retinoid binding proteins suggests their 
involvement in Wallerian degeneration (see part 3.2). Since Schwann cells were 
found to express all retinoic acid receptors they are considered possible candidates 
for RA-dependent gene regulation in the sciatic nerve (see part 3.1). At the same 
time, Schwann cells are the prime targets of the neuregulin signal via erbB2/erbB3 
(Caroll et al., 1997). In the light of these data and the recent findings of immediate 
erbB signalling after nerve injury (Kim et al., 2002) I have investigated the effect 
of retinoic acid on expression of neuregulin receptors erbB2 and erbB3 in Schwann 
cell primary cultures. 
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3.4.3. Materials and Methods 
Cell culture 
Primary cultures of Schwann cells were prepared from new-born Sprague-
Dawley rats and processed as described in 2.2. 
RT-PCR 
Total RNA was isolated using Trizol as described in 2.5. Samples of 500 ng 
total RNA were treated with DNase I (Invitrogen), reverse transcribed and cDNA 
was tested for the presence of erbB2 and erbB3 transcripts. For detailed protocols 
and primer sequences see 2.5.  
Quantitative PCR 
To measure the relative change of erbB2 and erbB3 mRNA expression after 
RA treatment, quantitative PCRs were performed by means of the Roche Light 
Cycler System (Roche) using the QuantiTect SYBR Green PCR Kit (Qiagen). The 
detailed description of cycler programming and quantification principle is 
described in 2.6. The PCR efficiencies (amplification per cycle) were for GAPDH 
1.65, for erbB2 and erbB3 2.00. For every RA concentration three to eight 
independent cell culture experiments with pairs of RA and DMSO treated Schwann 
cells were performed and statistically analysed with Jmp software (SAS institute). 
Western blotting 
For immunoblotting, Schwann cells were triturated in hypotonic buffer with 
protease inhibitors 1 mM PMSF, 1 µ M leupeptin, 1 % aprotinin. Protein extracts 
were separated with discontinuous SDS-PAGE (10% T, 3.3% C) and transferred by 
semidry blotting onto a nitrocellulose membrane. Detection of immunoreactivity 
was based on a peroxidase-conjugated goat anti rabbit secondary antibody and the 
enhanced chemoluminescence method. Detailed descriptions are in part 2.7.  
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3.4.4. Results 
 
Schwann cell primary cultures 
In the peripheral nervous system erbB2 and erbB3 are expressed by Schwann 
cells and, among other functions, serve as a putative triggers of Wallerian 
degeneration (Kim et al., 2002). As described above (3.1, 3.3), I found that 
Schwann cell primary cultures prepared from rat sciatic nerves express RA 
receptors and retinoid X receptors, as well as retinaldehyde dehydrogenases, 
cellular retinoid binding proteins and CYP26 (Fig. 3.1.2). Thus these cells may be 
both: the source and the sink of retinoic acid action. Further on I investigated 
erbB2- and erbB3 regulation by retinoic acid in Schwann cells. In addition to the 
expression of retinoid receptors, cultured Schwann cells expressed the neuregulin 
receptor erbB3 and the erbB2 tyrosine kinase (Fig. 3.4.1a). With an antibody 
against erbB3, the presence of this protein was demonstrated with Western blotting 
(Fig. 3.4.1b).  
 
 
 
Fig. 3.4.1. Expression of erbB2 and erbB3 in Schwann cell primary cultures 
from rat sciatic nerves. a Expression of erbB2 and erbB3 transcripts (RT-PCR) 
and b erbB3 protein (Western blot). Cells were treated 24 hrs with all-trans RA, 
concentrations in nM; bp: molecular weight markers at 100 bp (bottom band), 200 
bp, 300 bp etc.; kDa: position of protein molecular weight markers. The expected 
molecular weight of erbB3 is 185 kDa (Caroll et al., 1997). 
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Effect of retinoic acid on erbB2 and erbB3 transcript concentrations 
With Light Cycler RT-PCR I successfully amplified transcripts of erbB2 and 
erbB3 in Schwann cells (Fig. 3.4.2a). PCR-fragments, separated in an agarose gel 
stained with ethidium bromide, had the expected sizes (erbB2: 337 bp, erbB3: 307 
bp, Fig. 3.4.1a). In order to investigate dose-dependent effects of RA, cultures were 
then exposed to 0.1, 1, 10, 100 and 1000 nM all-trans RA for 24 hrs, and the 
mRNA expression of erbB2 and erbB3 was analysed with quantitative RT-PCR. The 
validity of these experiments was controlled by melting curve analysis (Fig. 3.4.2b) 
and gel electrophoresis of PCR products amplified with the Light Cycler (Fig. 
3.4.2c). An example of two experiments comparing RA-treated samples with the 
controls is shown in Figure 3.4.2a. The dotted horizontal line in the semi-
logarithmic graphs shows the level of background fluorescence used to determine 
the crossing points.  
With identical mRNA concentrations of GAPDH there was a slight increase of 
erbB2 transcript (Fig. 3.4.2a, upper panels, curve shifted 1.0 cycle to the left) and a 
5.3-fold up-regulation of erbB3 (Fig. 3.4.2a, lower panels, curve shift 2.4 cycles to 
the left). Figures 3.4.3a, b show the relative changes in transcript concentrations of 
erbB2 and erbB3 in response to five different doses of RA. While the effect on 
erbB2 was not significant, RA caused a highly significant increase in erbB3 
expression (ANOVA p<0.001). Concentrations of 0.1 nM to 10 nM RA induced a 4- 
to 5-fold up-regulation of erbB3 (*p<0.05, **p<0.01, corrected t-tests). Higher 
concentrations of 100 nM and 1 µ M RA had no significant effects. 
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Fig. 3.4.2 Changes in erbB2 and erbB3 mRNA expression of Schwann cells 
after retinoic acid treatment, quantitative RT-PCR. a Representative 
amplification curves with primers for erbB2 and erbB3. Broken lines represent 
results from Schwann cells, which were treated 24 hrs with 10 nM all-trans RA, 
continuous lines from DMSO-treated cells. While no RA-induced change is 
observed for the concentration of GAPDH, the left shift of crossing points after 
treatment indicates higher transcript concentrations of erbB2 and erbB3 in RA-
treated cells. After all quantitative RT-PCR runs the amplified fragments were 
characterised b by their melting curves (italicised erbB and GAPDH symbolise 
negative controls without RT), and c with agarose gel electrophoresis. Expected 
fragment sizes were 337 bp (erbB2) and 307 bp (erbB3). Three different RA 
concentrations: 1, 10 and 100 nM and DMSO treated cells (C) are shown. The six 
distinct marker bands have 600 (stronger band), 500, 400, 300, 200 and 100 bp. 
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Fig. 3.4.3 Relative quantification of mRNA concentrations 24 hrs after RA 
treatments. Data are normalised to transcript levels of the DMSO-treated Schwann 
cells. Error bars indicate standard error of mean. The effect of RA on erbB3 
expression was highly significant (ANOVA, p<0,001). A posteriori comparisons 
showed a significant up-regulation at 0.1 (n=5), 1 (n=6) and 10 nM (n=5) RA 
(corrected t-test,  *p<0.05, **p<0.01). The concentrations of 100 (n=5) and 1000 
(n=3) nM of RA showed no significant effects. 
 
Effect of retinoic acid on erbB3 protein expression 
Since discrepancies in transcript expression and protein synthesis are not 
infrequent, I evaluated erbB3 immunoreactivity in Schwann cell protein extracts 
with semiquantitative Western blotting experiments. To induce protein synthesis 
Schwann cells were treated with 0.1, 1, 10 and 100 nM all-trans RA for 40 hrs as 
described above. After SDS-PAGE, immunoreactive signals were evaluated with 
enhanced chemoluminescence and an Image Analyser. Consistent with the results 
on gene expression, the protein signals of erbB3 were raised (ANOVA, p<0.005; 
Fig. 3.4.4a, b). In these experiments, lower doses of RA (0.1 and 1 nM) were not 
significant, while 10 and 100 nM produced significant increases (Dunnett’s test).  
On the both expression levels, 10 nM t-RA produced the highest effect on 
erbB3 levels. 
 
 
 
 
 
 - 68 - 
 
 
Fig. 3.4.4 Increase of erbB3 immunoreactivity after retinoic acid treatment. a 
Western blot of Schwann cell protein extracts using the erbB3 antiserum; 10 µ g 
protein per lane. Cells were treated 40 hrs with DMSO (“0”, no RA) or all-trans 
RA (0.1, 1, 10 or 100 nM). Two strong bands represent erbB3 at around 185  kDa. 
b Quantification of the immunoreactive signal (both erbB3 positive bands 
combined; ECL, linear range of X-ray film). The RA effect was small but highly 
significant (n=3, ANOVA, p<0.001; post hoc comparisons with control *p<0.05, 
**p<0.01). Three independent experiments were performed, error bars indicate 
standard deviation. 
 
3.4.5. Discussion 
Recent experiments indicate that retinoic acid may act as a regulator of 
traumatic reactions after peripheral nerve injury (Zhelyaznik et al., 2003). The 
expression of CRABP-II was most altered during Wallerian degeneration and did 
not decline during at least two weeks after nerve transection, unless regeneration 
was allowed (part 3.2.2). This prompted me to suggest an involvement of RA in the 
process of Wallerian degeneration. Another piece of evidence backing this 
assumption is the fact that RA down-regulates the gene expression of CNTF in 
primary Schwann cell cultures (Johann et al., 2003), which was also noticed during 
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Wallerian degeneration in vivo (Sendtner et al., 1996). With the possible exception 
of this negative effect on ciliary neurotrophic factor, the physiological functions of 
retinoic acid during PNS regeneration are completely unknown. Using Schwann cell 
primary cultures from rat sciatic nerves I showed that retinoic acid exerts a 
significant regulatory effect on the expression of the neuregulin receptor erbB3. 
The dose-dependent effect of RA was obvious on mRNA and protein levels.  
β-NRG-1 and its receptors erbB2 and erbB3 are essential during Schwann cell 
differentiation (Jessen and Mirsky, 2002; Grinspan et al., 1996). In the late stages 
of nerve regeneration the proposed function of β-NRG-1 is to control development 
of neuromuscular reinnervation (Noll and Miller, 1994). While the function of β-
NRG-1 in the early stages of regeneration has not been studied in detail, several 
lines of evidence indicate that this pathway plays an important role during 
Wallerian degeneration as well. An increased expression of erbB receptors is 
observed immediately after nerve injury (Kim et al., 2002). It has been suggested 
that the immediate expression of β-NRG-1 in Schwann cells after nerve injury may 
prevent their apoptotic death (Grinspan et al., 1996), stimulate their proliferation 
and migration and may influence the production of chemotactic cues for 
macrophages which will clear myelin debris (Tofaris et al., 2002; Caroll et al., 
1997). The results of the present study point to retinoic acid as a possible regulator 
of these physiological responses. 
What is the molecular mechanism of the observed RA-dependent regulation of 
erbB3? Up to now, cancer research is the only field where studies concerning the 
molecular interaction of retinoids and neuregulins have been performed 
(Offterdinger et al., 1998; Tari et al., 2002; Schneider et al., 1999). In this context 
retinoid signalling has been identified as a key regulatory element at least for a 
subset of breast cancer types, where the application of retinoic acid down-regulates 
the expression of erbBs (Zou et al., 1994; Huang et al., 1988). None of the three 
erbB promoters contain classical retinoid response elements, whereas potential AP1 
sites are present in the erbB2 and erbB3 promoters (Offterdinger et al., 1998). 
Several molecular events are involved in the activation of AP-1: the transactivating 
potential of AP-1 depends on induction and phosphorylation of AP-1 components 
(c-fos and c-jun) by mitogen-activated protein kinase (MAPK). The expression of 
c-fos is regulated by ternary complex factors whose activity is regulated by the 
extracellular signal-regulated kinase p38 MAP kinase and c-Jun N-terminal kinase 
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(JNK). Expression of c-jun is regulated by ATF-2, which is phosphorylated by JNK 
and/or p38 MAPK. As said above, post-translational activation of AP-1 is also 
regulated by MAPK-mediated phosphorylation (Konta et al., 2001). RA is able to 
mediate both positive and negative regulatory effects on c-jun/c-fos depending on 
the cell type (Li et al., 1999). As for the negative mechanism, RAR upon ligand 
binding is able to disrupt c-jun/c-fos dimerization in vivo, which would preclude 
the formation of the DNA-binding component AP-1 complex. Another suggested 
mechanism is competition for the common co-activator cAMP-responsive element 
binding protein (CBP); (Zhou et al., 1999).  
The positive effect of RA on AP-1 is possibly mediated via the protein kinase 
C (PKC) protein (Desai and Niles, 1997). PKC, an intermediate signal  of the PLCγ 
signalling cascade, is thought to regulate gene expression by inducing the activity 
of the AP-1. RA increases the activity of PKCδ (Kambhampati et al., 2003), while 
on the other hand it prevents activation of PKCα (Radominska-Pandaya et al., 
2000). RA-induced differentiation of certain tumour cells is accompanied by an 
increase in PKC expression (Desai and Niles, 1997). Another suggested mechanism 
of the up-regulation of AP-1 activity due to RA treatment is the activation of 
MAPK pathway (Huang et al., 2003). Thus PKC and MAPK activity may correlate 
with the positive effect of RA on AP-1. One cannot exclude that the effect of RA 
on the β-NRG-1/erbB signalling requires activation of additional intermediates. It 
is known that the rapid increase of β-NRG-1 mRNA in vitro (Loeb et al., 2002) and 
at the neuromuscular junctions in vivo is induced by a number of regulatory factors, 
such as NT-3, NT-4, BDNF and GDNF (Loeb and Fischbach, 1997), which are also 
the targets of the transcriptional activity of RA in the variety of cell cultures (Mey, 
2001). Therefore a number of molecular mechanisms could account for the effect of 
RA on β-NRG-1/erbB signalling.  
While this remains to be studied, the observation that all-trans-RA doses as 
low as 0.1 and 1 nM potentiated erbB3 gene expression in Schwann cells suggests 
interactions of RA and β-NRG-1/erbB signalling in the PNS. This constitutes one 
possible biological function of retinoid signalling triggered by peripheral nerve 
injury. 
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4. General Discussion 
 Physiological functions of retinoic acid after nerve injury are almost 
unstudied, even though the potential of this molecule is enormous. During 
embryonic development RA regulates differentiation of brain cells (Noll and 
Miller, 1994; Wuarin et al., 1990; Henion and Weston, 1994) and in some cases 
promotes axonal regeneration in vitro (Corcoran and Maden, 1999; Corcoran et al., 
2000; Mey and Rombach, 1999). In some cell cultures unrelated to the nervous 
system, RA regulated the expression of many intracellular signals which take part 
in the physiology of nerve regeneration (Chang et al., 2000; Choudhury et al., 
2000; Mey, 2001). However, no experiments have so far been conducted to prove 
that functional retinoid signalling forms part of the traumatic reactions in the 
nervous system.  
In my work the presence of the retinoic acid signalling system was shown for 
the adult PNS (part 3.1), and the activation of RARE-regulated gene expression in a 
transgenic reporter mouse specifically after nerve lesion indicates the involvement 
of RA in traumatic processes following nerve injury. The possible scheme of 
retinoic acid signalling in the PNS is summarised in Fig. 4.1. 
Since the local distribution of RA synthesising aldehyde dehydrogenases is 
considered to determine the spatial and temporal activity of retinoic acid (Ross et 
al., 2000), their molecular levels and RA-synthesising activity were measured in 
sciatic nerves. While the enzyme activity of RALDH-2 was detected, no altered 
expression of either RALDH-2 or RALDH-1 and -3 was noticed (part 3.1, 
Zhelyaznik et al., 2003). Moreover, gene expression and immunoreactivity of 
CRBP-I (part 3.2), which is an indicator of cells that are able to synthesise RA and 
supports the enzymatic oxidation of retinol and retinal to retinoic acid, was found 
to be up-regulated. This corroborates the hypothesis of retinoic acid synthesis in 
sciatic nerves and its elevated expression after injuries of the PNS.   
The control of retinoic acid action after PNS injury may involve different 
mechanisms. They could include negative regulation by 1) RA-degrading enzymes, 
such as CYP26 (Mey, 2001; Swindell et al., 1999), 2) compartmentalisation of RA 
by CRABP-I (Dong et al., 1999a) and 3) competition of orphan receptors like 
COUP-TFII that interfere with DNA-binding of the retinoid receptors (McCaffery 
et al., 1999). The mechanisms of positive regulation may include changes in 
expression of 1) CRABP-II, which transports retinoic acid to its nuclear receptors 
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(Delva et al., 1999; Budhu and Noy, 2002) or 2) retinoid nuclear receptors, which 
activate gene transcription upon ligand (RA) binding.  
Thus, elevated concentrations of CRABP-II and RARs/RXRs may lead to 
enhanced transcriptional activity. Taking into account their physiological functions, 
molecular levels of these molecules were evaluated and shown to be strongly 
increased. The observation of a drastic up-regulation of CRBP-I and CRABP-II 
(part 3.2) after nerve transection (in degrading nerves) and an early raise of their 
expression after crush lesion or transection, suggests the involvement of retinoic 
acid signalling in Wallerian degeneration – the process which initiates axonal 
regeneration (Fawcett and Keynes, 1990). However, I cannot exclude that retinoic 
acid also mediates axonal regeneration directly, since the elevated levels of RARα, 
RXRα and RXRβ (part 3.3) were observed 7 days after crush lesion, when 
regenerating axons are most apparent.  
What exactly could have caused the increased expression of CRBP-I, CRABP-
II, RARα, RXRα and RXRβ after axotomy remains to be studied. We also do not 
know the cellular source of these molecules in vivo. At this point of time I can only 
speculate about the possible triggers. Wallerian degeneration and axonal 
regeneration are based on a corresponding sequence of cellular and molecular 
interactions, which in turn reflect the differential expression of specific genes with 
functions in nerve degeneration and repair. Comparing the gene expression and the 
time periods of action for different genes (Gillen et al., 1997) with the time course 
of expression of RA-system molecules, several possible candidates are obvious. 
They may include neuropoietic cytokines: interleukin (IL)-6, ciliary neurotrophic 
factor (CNTF) and leukemia inhibitory factor (LIF); neurotrophins: nerve growth 
factor (NGF) and brain derived neurotrophic factor (BDNF) and their receptors 
NGFR-p75, trkB and trkC; neuregulins; and transforming growth factor TGFβ.  
Within 24 hours after rat sciatic injury, LIF protein increases in Schwann cells 
close to the lesion site. It is then retrogradely transported in the axons and then 
functions as a neurotrophic factor for sensory and motorneurons (Mey, 2001). 
Although the expression of CNTF is down-regulated due to the injury, cell damage 
causes release of CNTF from those cells. CNTF, which is also taken up and 
retrogradely transported, prevents the degradation of motorneurons (Sendtner et al., 
1992). IL-6 is also induced by the nerve injury and supports macrophage activity 
like myelin breakdown, which in turn stimulates Schwann cell proliferation and 
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axonal regeneration (Gillen et al., 1997). The expression of the different members 
of the TGFβ family reach their maxima two or four days after injury and, apart 
from their important anti-inflammatory functions, stimulate Schwann cell 
proliferation (Mey, 2001).  Thus the expression of these factors may influence the 
up-regulation of CRBP-I and CRABP-II in the first days after injury.  
Triggered by a peripheral nerve injury, the expression of NGF, BDNF and 
their receptors goes up within a few hours, although another maximum of NGF 
expression is reached 3 days after the lesion, and in degenerating nerves its 
increased expression persists up to four weeks after nerve transection (Zhao and 
Schwartz, 1998). A second peak of BDNF expression is also observed. Two weeks 
after the injury this neurotrophin is expressed in Schwann cells, while the initial 
up-regulated expression in neurones returns almost to normal (Gillen et al., 1997). 
This delayed activation of NGF and BDNF may therefore influence the second 
expression peaks of CRABP-II and CRBP-I, as well as the elevated expression of 
retinoid receptors.  
Most probably, the cocktail of these cytokines could influence the expression 
of the retinoic acid signalling system. E.g., first CNTF and/or LIF, then NGF, 
BDNF and/or TGFβ. Obviously, a set of additional experiments is required to 
investigate these interactions. Specific silencing of different cytokines with siRNAs 
will allow to determine the contribution of each of them in the regulation of 
elevated expression of CRBP-I, CRABP-II, RARα, RXRα and RXRβ after 
axotomy. 
Even though my experiments point to the Schwann cells as a possible cellular 
source of retinoid receptors, additional experiments are also required here. What 
is/are the source of retinoic acid? Are Schwann cells the only targets of RA 
transcriptional action? My experiments with dorsal root ganglia showed the 
presence of CRBP-I and CRABP-II in the sensory nerve cells, however, their 
expression was not affected by a degenerating or regenerating injury. Thus, nerve 
cells are possibly neither the source, nor the target of retinoic acid action during 
PNS injury. Fibroblasts and macrophages contribute to the supply of neurotrophic 
and neurotropic factors in the injured nerves. Recent experiments with spinal cord 
lesions (P. McCaffery, unpublished observations) point to the possible involvement 
of fibroblasts in retinoid acid synthesis. These cells are immuno-positive for 
RALDH-2, which enzymatically synthesises RA. There is no direct evidence of 
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macrophage involvement in the activation of the RA-system, however, the peak of 
their infiltration happens at the second day after lesion and remains high up to four 
weeks post axotomy, coincident with the elevated expression of CRBP-I and 
CRABP-II. Thus the investigation of these two cell types is required in the future. 
Here I would like to propose a possible scheme of the retinoic acid system 
signalling response to the nerve injury (Fig. 4.1): after injury, RA is synthesised 
due to RALDH-2 activity in the presence of increased CRBP-I. The up-regulation 
of CRABP-II will then facilitate RARE- and/or AP-1–regulated gene activation 
during Wallerian degeneration by trafficking RA to the nuclear receptors, the levels 
of which are also increased. The proposed scheme represents the normal signalling 
pathway of retinoic acid during development (McCaffery et al., 1999). Since no 
direct comparing of the levels of the molecules involved in retinoid signalling in 
regenerating PNS and during embryonic development has ever been done, I can 
only speculate about the similarities. The activation of members of the pathway 
shown in my study allows to suggest that the similar signalling cascades are taking 
part in regenerating sciatic nerve and during embryogenesis. However the 
involvement of CRABP-I, CYP26, and the regulation of AP-1 in sciatic nerves 
remains unknown.  
Many genes related to the regulation of Wallerian degeneration count among 
the targets of RA. They include neurotrophin receptors and cytokines as well as 
different transcription factors. Up to now only three possible physiological effects 
of RA are observed in the PNS. All of them were derived, however, from 
experiments in vitro. RA autoregulates the gene expression of its own nuclear 
receptors (part 3.3), exerts a negative effect on CNTF expression (Johann et al., 
2003) and up-regulates the expression of β-NRG-1 receptor erbB3 (part 3.4), which 
is essential during Schwann cell differentiation (Grinspan et al., 1996; Jessen and 
Mirsky, 2002), and takes part in Wallerian degeneration (Caroll et al., 1997; Kim et 
al., 2002). The regulation of erbB3 expression by retinoic acid is another piece of 
evidence for the RA involvement in biological processes of Wallerian degeneration 
and confirms the hypothesis that retinoid signalling is triggered by peripheral nerve 
injury.  
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Fig. 4.1. Possible scheme of retinoic system response to the nerve injury.  
Retinol is oxidised in retinoic acid (RA) via retinaldehyde (RAL) intermediate. This 
process is catalysed by retinaldehyde dehydrogenases (RALDH) in the presence of 
cellular retinol binding protein (CRBP)-I. RA is then either stored after binding  to 
the cellular retinoic acid binding protein (CRABP)-I and further catabolised by 
cytochrome (CYP)-26 to 4-oxo-RA or 4-OH-RA, or  transferred to the nucleus due 
to the CRABP-II activity. There it can influence gene expression after binding to 
the retinoic acid receptors (RAR) or retinoid X receptors (RXR), which activate 
retinoic acid response elements (RARE) or transcription factors like activating 
protein (AP)-1. As a response to this gene activation, ciliary neurotrophic factor 
(CNTF) and(or) β-Neuregulin-1 receptor erbB3 expression is mediated. 
Alternatively, RA signalling can be silenced by the orphan receptors COUP-TFII, 
which interfere with DNA-binding of the retinoid receptors.   
 
The molecular mechanisms described in this work extend our understanding of 
the processes following peripheral nerve injury. According to my data, one more 
signalling cascade – the retinoic acid system – takes part in these processes. 
However, my findings raise several open questions, some of which were already 
mentioned above. The most important of them concerns the exact role of retinoic 
acid after axotomy. The indirect pieces of evidence of RA involvement in Wallerian 
 - 76 - 
degeneration guide further possible experiments to prove its role there. Such 
experiments may include the investigation of the physical features of Wallerian 
degeneration (Schwann cell de-differentiation, monocyte invagination, myelin 
phagocytosis, etc.) or molecular levels of the key molecules involved in these 
processes (TGFβ, p75, β-NRG-1, etc.). To investigate the role of RA, either the 
systemic injections of retinoic acid or the use of the transgenic animals with a 
manipulated RA-system are required.  
The role of retinoic acid in regeneration is to be another topic of subsequent 
investigations. Since tropic functions of RA are known from developmental studies, 
does it provide guidance cues during regeneration of adult PNS? Does it influence 
the production of trophic factors essential for regeneration? Does it influence 
myelination or the re-innervation of muscle?  
Answers to these questions will enable us to develop more effective 
pharmacological strategies for neurodegenerative diseases and traumatic injuries.  
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5. Summary 
Although the problem of nerve regeneration has been studied since the beginning of the 
20th century, the molecular mechanisms of this process are still largely unknown. Recently, 
the involvement of retinoic acid (RA) signalling was also proposed to regulate PNS 
regeneration based on its regulation of a variety of intercellular signals, which take part in the 
physiology of nerve regeneration. However, no experiments have so far been conducted to 
prove that functional retinoid signalling forms part of the traumatic reactions in PNS. The 
results of my thesis allow to confirm this hypothesis: With RT-PCR and immunoblotting all 
necessary components of the RA signalling pathway were detected in the sciatic nerve of 
adult rats. These are retinoic acid receptors, retinoid X receptors, the retinoic acid 
synthesising enzymes RALDH-1, RALDH-2 and RALDH-3, and the cellular retinoid binding 
proteins CRBP-I, CRABP-I and CRABP-II. Although the transcript levels of RALDHs were 
not significantly altered by a sciatic nerve injury, sciatic nerve crush and transection resulted 
in a more than 10-fold up-regulation of CRBP-I mRNA, a protein which is thought to 
facilitate the synthesis of RA. Transcript and protein levels of CRABP-II were elevated 15-
fold. This is a possible mediator of RA transfer to its nuclear receptors. The expression of 
retinoid binding proteins remained elevated during and two weeks after nerve transection, 
thus the involvement of these proteins in the first phase of axonal regeneration – Wallerian 
degeneration – may be assumed. Other key molecules of RA regulation are its nuclear 
receptors, the expression and immunoreactivity of which was measured in the next part of my 
work. Seven days after crush, the protein levels of RARα , RXRα and RXRβ  were 
significantly up-regulated (4-, 2- and 1.5-fold respectively). On the mRNA level, all three 
RARs and RXRα were elevated as well. In order to investigate putative biological effects of 
RA, Schwann cell were investigated. These cells were found to express all components of the 
retinoic acid signalling cascade and thus can be the source of RA and the target of its 
functions. I discovered that retinoic acid autoregulates the gene expression of RARβ and 
RARγ in Schwann cells, as well as the expression of erbB3, an important signalling 
intermediate during Wallerian degeneration. These findings confirm our hypothesis of an 
involvement of RA in Wallerian degeneration. However, they rise a number of open questions 
about the cellular source of RA signalling, the trigger of its activation and the downstream 
mechanisms of RA action. The answers to these questions in the future will enable the better 
understanding of the molecular processes of PNS regeneration.   
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5. Attachments 
 
Abbreviations  
 
AP-1    – activator protein - 1 
APS    – ammonium persulfate 
ARIA    – acetylcholine receptor-inducing activity 
ATF-2    – activating transcription factor - 2 
BCA    – bicinchoninic acid 
BCIP    – 5-bromo-4-chloro-3-indolyl phosphate, toluidine salt 
BDNF   – brain derived neurotrophic factor 
BSA    – bovine serum albumine 
CNS    – central nervous system 
CNTF    – ciliary neurotrophic factor 
COUP-TFII   – chicken ovalbumine upstream promoter-transcription factor II 
CRABP   – cellular retinoic acid binding protein 
CRBP    – cellular retinol binding protein 
CYP 26   – cytochrome P 450-oxidase, number 26 
DAB    – diamino-benzidine 
DEPC    – diethyl-pyrocorbonate  
DIG    – digoxigenin 
DMEM   – Dulbecco’s modified Eagle’s medium 
DMSO    – dimethyl sulfoxide 
DNA    – deoxyribonucleic acid 
DPX    – p-Xylene-bis(N-pyridinium bromide) 
DR    – direct repeat 
DRG    – dorsal root ganglion 
ECL    – enhanced chemilumeniscence 
ECM    – extracellular matrix 
EcoR1    – Escherichia coli restriction endonuclease I 
EDTA   – ethylendiamine - tetra acetic acid  
EGF    – epidermial growth factor 
ELISA    – Enzyme-Linked Immunosorbent Assay 
erbB    – erythroblastosis gene B 
ERK    – extracellular  signal-regulated kinase 
FCS    – fetal calf serum  
GAM Ig   – goat anti mouse immunoglobulin 
GAPDH   – glyceraldehyde phosphate dehydrogenase 
GAR Ig   – goat anti rabit immunoglobulin 
GDNF   – growth derived neurotrophic factor 
HEPES   – N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid  
HDAC    – histone deacetylase 
HRP    – horseradish peroxidase 
ISH    – in situ hybridisation  
IL    – interleukin  
Jak    – Janus kinase 
lacZ    – E. coli β-galactosidase (reporter) gene 
LB    – Luria-Bertani 
MAPK    – mitogen activated protein kinase 
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NBT    – nitro blue tetrazolium chloride 
NGF    – nerve growth factor 
NGS    – normal goat serum 
NMRI    – Naval Medical Research Institute 
NRG    – Neuregulin 
NT    – neurotrophin  
dNTP    – 2'-Deoxyribonucleoside-5'-tri-phosphates 
OLN-93   – oligodendrocyte cell line 93 
p75    – protein 75  
PAGE    – polyacrylamide gel electrophoresis 
PBS    – phosphate buffered saline 
PCR    – polymerase chain reaction  
PFA    – paraformaldehyde  
PI3P    – phosphatidylinositol 3-phosphate  
PKC    – protein kinase C 
PLCγ    − phospholipase C γ 
PMSF    – phenylmethylsulfonylfluorid 
RA    – retinoic acid 
RALDH   – retinaldehyde dehydrogenase  
RAR    – retinoic acid receptor 
RARE   – retinoic acid response element 
Raf    – Ras associated factor 
Ras    – rat sarcoma viral oncogene homolog  
RNA    – ribonucleic acid  
RT    – reverse transcription 
RXR    – retinoid X receptor 
RXRE   – retinoid X response element 
SEM    – standard error of mean 
SD    – standard deviation 
SDS    – sodium-dodecylsulfate  
SSC    – sodium citrate  
TBS    – Tris buffered saline  
TBS-T    – TBS-Tween 20 
TEMED   – N,N,N',N'-tetramethylethylenediamine 
TGFβ    − transforming growth factor β 
Tris     – tris-(hydroxymethyl)aminomethane 
Trk    – tropomyosin related kinase 
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